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Summary 
Haemoglobin is a molecule present in red blood cells and is essential for 
adequate oxygen delivery to tissues. It is measured frequently in many 
clinical situations, particularly intraoperatively. Until recently, it was only 
possible to measure haemoglobin through blood testing which is an 
invasive process and requires some time to process. Devices have been 
developed in the last number of years to minimise both the invasiveness 
and time needed to measure haemoglobin. More recently, devices are 
available that provide instant or continuous results without requiring 
blood samples but these have not been universally accepted into clinical 
practice.  
Stroke volume is the amount of blood ejected from the heart at each 
heartbeat, and is one of the determinants of cardiac output (which is also 
responsible for ensuring adequate tissue oxygen delivery). It varies 
across many clinical states, particularly following major haemorrhage or 
reduced cardiac function. The analysis of variations in stroke volume 
during the respiratory cycle (i.e. between the end of a complete 
exhalation and the end of the following complete exhalation) has been 
shown to predict when a patient’s stroke volume could be improved by 
administering intravenous fluid. Successfully identifying such ‘responders’ 
can lead to earlier appropriate treatment, and also avoid over-treatment. 
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However, at present the most reliable methods of measuring stoke 
volume or predicting fluid responsiveness involve the use of invasive 
devices which have the potential to be harmful. 
A novel device has been developed which uses the absorbance of red 
and near-infrared light across a finger tip as the basis for the 
measurement of both haemoglobin and stroke volume, along with the 
prediction of fluid responsiveness. This is non-invasive and would allow 
for the continuous measurement of these physiological parameters, with 
potential for more efficient and timely treatment.This thesis presents the 
first clinical evaluation of the two functions of this novel device across 
three studies. 
The first study investigated the measurement of haemoglobin by this 
device across twenty five patients undergoing heart surgery who each 
underwent four samples. The second study looked into the measurement 
of haemoglobin in one hundred pregnant women during their twenty-
week antenatal clinic visit. In both studies, the results from the device 
were compared with the standard laboratory method of measurement. 
The third study investigated the device’s ability to measure stoke volume 
and to predict fluid responsiveness in twenty patients undergoing heart 
surgery. 
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The results of these studies showed that the device is currently not 
suitable for use in clinical practice as a replacement for the more 
established methods of measurement one each case. Some explanation 
is offered regarding the poor results.  
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1.Introduction 
1.1.Thesis application and proposal 
The application for MD degree by thesis in Anaesthesia and Intensive 
Care Medicine was approved by the Faculty of Medicine at University 
College Cork in October 2011. 
There is a change to the analyses performed on the data collected 
during the third clinical trial (“Evaluation of a novel, non-invasive method 
for the estimation of stroke volume and the prediction of fluid 
responsiveness.”). It was not possible to construct both Bland-Altman 
and polar plots as initially planned, as to do so would require the novel 
device to output in units equivalent to those of the reference technique, 
which is not the case. In addition, a receiver operating characteristic 
(ROC) curve was constructed in order to analyse the ability of the novel 
device to predict subjects’ responsiveness to the administration of 
intravenous fluids. This is further documented in the discussion section of 
chapter 4. 
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1.2.Perioperative photoplethysmography – history and 
recent developments  
Intraoperatively, it is routine to monitor blood pressure, heart rate, 
oxyhaemoglobin saturation, respiratory rate, end-tidal oxygen and 
carbon dioxide partial pressures, and the electrocardiogram. During 
major surgery, more advanced and increasingly invasive monitoring can 
be instigated, such as intra-arterial blood pressure, central venous 
pressure, and transoesophageal echocardiography. Blood sampling is 
currently necessary to measure plasma haemoglobin concentration. 
Ideally, these physiological variables would be measured continuously 
and non-invasively. The following is a list of the ideal characteristics of 
such a monitor: 
• Non-invasive (no blood sampling or intra-vessel catheterisation 
would be necessary) 
• Accurate 
• Reliable 
• Fast (minimal time delay between commencement of monitoring 
and the displayed result) 
• Continuous (allowing the identification of trends in evolution) 
• Free from artefacts (such as motion or external light sources) 
• Electrically safe (no direct harm from the device to the patient) 
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• Requires minimal skill to operate 
• Easily interpretable results 
• Robust 
• Portable 
• Economically advantageous (reusable, inexpensive capital 
expenditure, indirect savings from decreased use of single-use 
items and laboratory equipment) 
• Improved patient outcomes 
Photoplethysmography (PPG) has met many of these characteristics 
already, specifically in relation to oxyhaemoglobin monitoring. However, 
new applications of PPG continue to be discovered with the potential for 
improved patient outcomes and cost savings. This chapter reviews the 
history of the development of PPG and the expanding applications of 
this technology relevant to the anaesthetist in the intraoperative setting. 
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1.3.The beginnings of photoplethysmography 
‘Plethysmography’ derives from the Greek words ‘plethysmos’, meaning 
‘to increase’ and ‘graphos’, meaning ‘something drawn or written’1. In 
medical research and clinical use, a plethysmograph can be described as 
an instrument that can measure changes in volume over time2. PPG is the 
analysis of changes in the volume of blood passing through a region of 
the body using the variable absorption of specific wavelengths of light 
between a light source and a detector3. Two types of PPG are used – 
reflective PPG and transmission PPG. Reflective PPG refers to positioning 
of the detector next to the light source and measures the absorption of 
backscattered light with changes in blood volume. More commonly, 
transmission PPG is used, whereby the light source and detector are 
placed opposite each other across the region to be studied. Alrick 
Hertzman reported the development of transmission PPG in 19374 and 
described the relationship in humans between blood volume changes 
recorded by reflective PPG and those recorded by mechanical 
plethysmography the following year5. 
In the 1940s Hertzman and his colleague John Dillon found the PPG 
waveform to be made up of two main components, which are now 
known as AC and DC6. The DC component represents light absorption 
due to venous and non-pulsatile arterial blood, along with that due to 
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the various body tissues3. The AC component represents the variation in 
light absorption caused by the temporary increase in blood volume of 
the sample region due to arterial pulsation. Modern PPG equipment can 
usually display only the AC component of the signal1. 
Although much of the research into PPG has led to advances in the 
assessment of vascular diseases7 and autonomic function8, this review 
will focus on the perioperative use of PPG to monitor physiological 
functions that can benefit the anaesthetist in the safe management of the 
patient in the operating theatre. PPG can also be used to non-invasively 
monitor respiratory rate, but as alternative methods are available for this 
purpose in the perioperative environment, this application of PPG will 
not be considered here. 
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1.4.Pulse oximetry and heart rate monitoring 
Karl Matthes was the first to describe the measurement of 
oxyhaemoglobin saturation in a human by comparing the absorption of 
light of two wavelengths (red and green) at the ear9. World War II and 
the expanding role of the air force accelerated interest in the non-
invasive monitoring of oxyhaemoglobin saturation. As fighter planes 
were unpressurised, pilots would frequently lose consciousness at higher 
altitudes due to hypoxia. This led to American researcher Glenn Millikan’s 
1942 publication in which he described a lightweight device for 
measuring oxyhaemoglobin that fitted over the ear (based on Matthes’ 
prior work) and coined the term “oximeter”10. Unfortunately, Millikan’s 
oximeter was not very helpful in aviation as it was very susceptible to 
motion-artefacts. Meanwhile, J Squire in London developed a device 
which first squeezed the blood out of a web space of the hand and 
measured absorbance using red and infrared light for zero calibration, 
and then again with blood flow restored11. His work is considered the 
immediate forerunner of modern pulse oximetry12. Earl Wood improved 
upon Squire’s idea by modifying Millikan’s device for the ear to include a 
compression system and also an improved infrared filter13. Wood’s newer 
system went on to be used clinically but was not very reliable.  
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In the early 1970s, at the Research Division at Nihon Kohden 
Corporation, Japan, Takuo Aoyagi ran into difficulties attempting to use 
a similar technique to Wood’s to measure cardiac output at the ear using 
a dye densitometry method. An artefact caused by arterial pulsation 
interfered with the dye dilution curves obtained. Thinking back to the 
earlier studies of oximetry, Aoyagi realised that periods between this 
‘noise’ could be used as zero calibration against the arterial pulsation 
and so he conceived the principle upon which pulse oximetry is now 
based. Subsequently, he chose the wavelengths 630 nm and 900 nm for 
transmission PPG and calculated the “ratio of ratios” (the ratio of AC/DC 
intensity for each wavelength, and then the ratio of these). This ratio 
correlated well with arterial oxyhaemoglobin saturation14. Nihon Kohden 
failed to develop Aoyagi’s system further, and so the first commercially 
available pulse oximeter became Minolta’s OXIMET MET-1471 in 1977. 
As miniaturisation allowed for smaller devices, including the use of 
cheaper and more versatile light-emitting diodes (LEDs), pulse oximeters 
began to be used by anaesthetists in operating theatres. An anaesthetist 
working at Stanford University, William New, had noticed that colleagues 
would borrow pulse oximeters (normally kept in the respiratory 
laboratories) for use during particularly complex cases and he sought to 
capitalise on this phenomenon by setting up Nellcor in 1981. Nellcor 
released their pulse oximeter (the Nellcor N-100) in 1983, which was the 
first device to introduce a sound to accompany each detected pulse 
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along with a clear change in pitch as oxygen saturation varies. It 
therefore also gave measured heart rate. The first published evaluation 
of the Nellcor N-100 was written by New himself15. 
Although the renowned anaesthetist, academic and historian J W 
Severinghaus noted that the introduction of pulse oximetry coincided 
with a 90% drop in intraoperative mortality12, major studies have not 
proven this association to be true16. Indeed, the most recent Cochrane 
Review on the subject concluded that “despite an intense methodical 
collection of data from a relatively large general surgery population, … 
the value of perioperative monitoring with pulse oximetry is questionable 
in relation to improved reliable outcomes, effectiveness and efficiency”17. 
Nevertheless, pulse oximetry is today considered essential for the safe 
conduct of anaesthesia and is acknowledged as a minimum standard for 
the monitoring of oxygenation by many professional bodies18-20. 
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1.5.Plasma haemoglobin concentration 
Oxygen delivery to tissues is dependent upon plasma haemoglobin 
concentration (Hb), oxygen and cardiac output and may be calculated 
using the equation: 
Oxygen Delivery = [1.39 x Hb x SaO2 + (0.023 x PaO2)] x CO 
where 
SaO2 = arterial oxyhaemoglobin saturation (percentage of total 
haemoglobin that is oxygenated) 
PaO2 = partial pressure of oxygen in arterial blood (kilopascals) 
CO = cardiac output (litres/minute) 
The lower limit of normal of Hb is generally accepted as 130 g.l-1 for 
males and 120 g.l-1 for females21, and large intraoperative decreases in 
Hb (to levels as low as 70 g.l-1 for example) can result in up to a 50% 
decrease in oxygen delivery to tissues. As tissue hypoxia can lead to 
organ dysfunction or failure, it is clear that monitoring of Hb must be an 
important focus of perioperative patient management. Indeed, 
laboratory blood testing is carried out an estimated 4-5 billion times per 
year in the United States22, with the estimation of plasma haemoglobin 
(Hb) concentration making up over 400 million of these tests23. 
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Preoperative anaemia is known to be associated with worse outcomes, 
including an increased risk of mortality, longer hospital length of stay, 
increased frequency of intensive care admission and increased frequency 
of requirement for post-operative ventilation24, 25. It is possible that the 
treatment of pre-operative anaemia can mitigate these risks. 
Intraoperatively, Hb may fall due to blood loss or haemodilution from 
intravenous fluid administration leading to the need for blood 
transfusion. Hb monitoring may also identify bleeding not otherwise 
apparent leading to location and treatment of the cause. Higher 
postoperative Hb is associated with fewer readmissions26. 
Patients undergoing cardiac surgery experience large changes in Hb due 
to major blood loss, haemodilution (particularly on the instigation of 
cardiopulmonary bypass) and the likely administration of blood products. 
Major bleeding in cardiac surgery was shown to be independently 
associated with operative mortality in one study. In addition, the same 
study also found that preoperative anaemia and blood transfusion were 
also associated with operative mortality27. Frequent Hb estimation is 
therefore an important feature in the perioperative management of 
major surgery such as cardiac surgery.  
According to the World Health Organisation, 18% of pregnant women in 
industrialised countries are anaemic28. It is likely that this prevalence is 
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higher in developing countries where proximity to suitable laboratories 
limits accurate testing. Iron-deficiency anaemia in pregnancy is 
associated with lower birth weight due to increased rates of pre-term 
birth although studies have not yet conclusively demonstrated that iron 
supplementation leads to improved clinical outcomes29. Nevertheless, as 
it is considered unethical to not treat antenatal anaemia, identifying 
anaemia remains an important part of antenatal screening. 
The laboratory gold standard for plasma haemoglobin estimation is the 
cyanmethaemoglobin method (HiCN)30. As this method involves the use 
of the highly toxic reagent potassium cyanide, cyanide-free methods are 
now more common in the clinical setting with device such as the Sysmex 
XE-2100 (Sysmex Corporation, Kobe, Japan)31. The newer automated 
methods can use combinations of flow cytometry and fluorescence to 
estimate Hb and can also obtain further information such as differential 
cell count. However, there can be significant delays in transporting blood 
samples to laboratories, with further delays involved both in processing 
the sample and in providing clinicians with the result, which can lead to 
late treatment in emergency situations. 
Arterial blood gas analysis machines can be used as point-of-care 
devices to provide a more rapid estimation of plasma haemoglobin, but 
the results must be used with caution as the limits of agreement between 
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these and laboratory-based estimations can be wide32. A handheld 
device for point-of-care measurement of plasma haemoglobin, the 
HemoCue (HemoCue, Ängelholm, Sweden) has been available for many 
years but can underestimate the true value of plasma haemoglobin and 
some authors recommend against using the HemoCue as a full 
replacement for laboratory-based estimation33, 34. 
The above methods involve the sampling of blood which can be painful 
for the patient and includes the risks of infection and of accidental 
needlestick injury to the proceduralist. Although rare, repeated blood 
sampling can lead to anaemia35 particularly in neonates (although this 
risk is not likely with the HemoCue). 
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1.6.Non-invasive, continuous haemoglobin 
measurement 
None of the above methods allow a continuous means of monitoring 
plasma haemoglobin concentration. Continuous monitoring in the 
operating theatre would allow the anaesthetic and surgical teams to 
identify trends in haemoglobin concentration due to haemodilution or 
blood loss and initiate earlier treatment23. In the case of pulse oximetry, it 
was the real-time, continuous and non-invasive nature of the device that 
allowed anaesthetists to identify when arterial oxygen saturation was 
falling before it had become clinically dangerous36. A continuous, non-
invasive Hb monitor might prove to be similarly useful. 
Sysmex Corporation (Kobe, Japan) launched the Astrim in 1999, which 
was the first device to utilise PPG for the continuous and non-invasive 
measurement of Hb37. This device used a charge-coupled device camera 
to detect light of wavelengths 660, 805 and 880 nm shone through a 
fingertip. Kinoshita et al were the first to investigate this device in 2002. 
The investigators found a good correlation between the novel device 
(Astrim, Sysmex Corporation, Kobe, Japan) and a laboratory reference 
(r=0.896) in healthy volunteers, but poor correlation in a group of 
patients with multiple myeloma (r=0.488)38. They did not present figures 
for bias (mean of the differences between the paired samples of the 
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methods of measurement) or limits of agreement as per the Bland-
Altman method for assessing agreement between methods of 
measurement39. Saigo et al later investigated the effect of the presence 
of white blood cells and platelets on the performance of the Astrim (ex-
vivo and in-vivo) and found that the results were unaffected37. Despite 
this promising start, the Astrim was not accepted into clinical use for Hb 
measurement. This is likely due to its large size and a design which 
would not be conducive to intraoperative use. In the meantime, Sysmex 
appear to have developed the Astrim system for use by athletes in a 
non-clinical setting. 
Noiri et al in 2005 described the use of a device manufactured and 
patented by Nihon-Kohden (the company behind Takuo Aoyagi’s original 
pulse oximeter), and found the bias between the non-invasively recorded 
Hb and the laboratory-determined Hb to be 0.00 g.l-1 and -1.6 g.l-1 in 
each of their patient groups with r2=0.81 and 0.75 respectively40. This 
device used four wavelengths (660, 805, 940 and 1300 nm) instead of 
the Astrim’s three. No further published investigations into this device 
appeared until 2013 when Toyoda et al concluded that the device could 
not replace laboratory Hb measurement and that it could not be used for 
decision-making in relation to blood transfusion41. It is not clear as to 
why Nihon-Kohden appear to have abandoned development of this 
device, although it should be noted that Nihon-Kohden announced an 
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expanded licensing agreement with Masimo in December 2008 which 
saw some integration of both companies’ monitoring devices. 
An alternative device called the NBM-200MP (OrSense, Nes Ziona, Israel) 
received FDA approval in 2010. The device operates using the principle 
of occlusion spectroscopy and consists of a ring-shaped probe 
containing a pneumatic cuff that fits over the base of a finger. In order to 
measure Hb, the cuff inflates to just above systolic blood pressure which 
temporarily occludes blood flow in the finger. The different absorption of 
light of various wavelengths between 600 and 1500 nm before and after 
occlusion allow the calculation of Hb. However, it takes 90 seconds to 
determine Hb each time, and therefore cannot truly be said to be 
continuous. Despite this, the device could potentially find an application 
in intraoperative care. The first clinical evaluation of the NBM-200MP to 
be published in peer-reviewed literature appeared in early 201242. For 
the purposes of this review, 9 trials were identified (as of 19th March, 
2020) which carried out clinical evaluations of the NBM-200MP 
compared to laboratory reference methods, and these are summarised in 
Table 1. Two of these trials did not report the limits of agreement 
between the methods of Hb measurement43, 44. The study by Coquin et 
al45 was stopped early following an interim analysis due to the poor 
performance of the device in patients admitted to an intensive care unit 
with gastrointestinal bleeding. The remaining studies reported broad 
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limits of agreement, which calls into question the clinical usefulness of 
the NBM-200MP. Importantly, none of the studies evaluated the use of 
the device in the intraoperative setting. 
Masimo Corporation (Irvine, California, USA) first introduced non-invasive 
Hb monitoring in 2008, and the technology is now incorporated into two 
devices; the Radical-7, a bedside monitor; and the Pronto-7, a handheld 
monitor. Of these, only the Radical-7 offers continuous Hb monitoring. 
Either device functions via PPG using greater than seven wavelengths of 
light (Masimo have not published the exact number of wavelengths, nor 
the precise wavelengths used).  
The first evaluation of the Radical-7 was described in an abstract in 
200746, and interest gradually increased with more and more agreement 
studies between the Radical-7 and various reference devices being 
published. This culminated in a systematic review and meta-analysis of 
non-invasive Hb monitoring devices by Hiscock et al, which included 18 
studies of the Radical-7, 6 of the Pronto-7, and 19 studies of various 
HemoCue devices47. The authors found no bias in the Masimo devices 
and a small fixed bias of 5.3 g.l-1 in one of the HemoCue devices. 
However, the limits of agreement for both Masimo devices 
(approximately ±30 g.l-1) were quite large, limiting their usefulness as an 
independent guide to blood transfusion decision-making. In a first of its 
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kind study, published after Hiscock et al’s systematic review, the use of 
the Radical-7 in orthopaedic surgery was associated with a 4% reduction 
in the risk of a patient receiving an intraoperative blood transfusion48. If 
this trend was borne out by further studies, it may lead to patient 
benefits resulting from reduced potential for the ill effects of transfusion, 
as well as reduced overall healthcare costs. However, Galvagno et al 
found that the Radical-7 “did not enhance the ability to predict the need 
for blood transfusion” in trauma patients, when added to the combined 
measures of age, sex, pre-hospital heart rate, SpO2, and admission heart 
rate49. Indeed, one study found a potential “error” incidence of 13% 
(defined as where the Radical-7 gave a Hb measurement of ±10 g.l-1 
where the reference value was <90 g.l-1); this could lead to transfusion 
where none was required, or the withholding of necessary transfusion50. 
Further, there is evidence to suggest that the performance of the 
Radical-7 worsens as a patient’s perfusion state worsens (as may occur in 
critically ill patients)51, which would suggest caution in the intraoperative 
use of this device in any patient suffering from shock, or in cardiac (or 
other major) surgery where patients are more likely to require the use of 
vasopressors following separation from cardiopulmonary bypass.  
There has been much commentary on Masimo’s devices in the published 
literature. Morey at al argue that a fundamental problem with most of the 
method comparison studies published to date is their tendency to mostly 
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feature data pairs where the reference Hb is above the range 60-100 
g.l-1, values which may not trigger a “decision to transfuse”52. Clearly, an 
error of ±30 g.l-1 as per the review by Hiscock et al47 is far less a problem 
where a patient’s true Hb is 120 g.l-1 than if it was 60 g.l-1.  
More recently Barker et al36 have suggested that these devices’ real 
value lies in their ability to monitor the trend in Hb, rather than the 
absolute value per se. Monitoring Hb trend would allow the anaesthetist 
to “(a) detect decreasing Hb when it is assumed to be stable; (b) identify 
stable Hb values when they are assumed to be decreasing; and (c) 
identify increases in Hb when they are assumed not to be increasing”. 
This may prompt the anaesthetist to carry out a laboratory Hb 
measurement sooner in the case of a downward trend on the monitor 
and take further action as appropriate. Barker and colleagues also make 
the case that as up to 31% of transfusions in operating theatres are 
carried out in the absence of formal Hb results, clearly there are 
occasions when there simply isn’t enough time to wait for a laboratory 
result. In these situations, a continuous monitor may either provide 
reassurance that there is enough time to send a blood test, and possibly 
avoid a transfusion, or indicate instead that a transfusion will be 
necessary immediately. 
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As Morey and Rice’s papers concluded52, 53, further study into the 
performance of these devices in the critical Hb range of 60-100 g.l-1 will 
need to be made, along with alternative measures of agreement such as 
those suggested previously by Clarke in relation to glucose monitors 
(error grid analysis)54. In the future, from an anaesthetist’s perspective, 
the most important marker of how well continuous non-invasive Hb 
monitoring performs will be how reliable our decisions regarding blood 
transfusion will be. For now, trending patterns can help raise the 




Intraoperatively, patients may require the administration of intravenous 
(IV) fluids in order to increase cardiac preload (left ventricular end-
diastolic volume) and subsequently improve cardiac output and blood 
pressure. IV fluids are also administered in the setting of circulatory or 
septic shock. However, patients will only respond to fluid administration 
if their myocytes are operating on the ascending portion of the Frank-
Starling curve55. It is also well known that patient outcomes are worsened 
if excessive fluid is administered56, and so there is a need to establish in 
advance whether or not a patient is likely to respond to a fluid bolus. 
Traditional measures, such as central venous pressure (CVP), have been 
shown to be unhelpful in identifying those patients who would benefit 
from fluid administration55. Echocardiography can be useful but is not 
always available or practical and requires a skilled operator. A method of 
non-invasively assessing fluid responsiveness would allow for more timely 
intervention with minimal harm to the patient. 
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1.8.Pulse oximetry plethysmographic variation and 
Plethysmographic Variability Index as monitors of fluid 
responsiveness 
Mechanical ventilation is well known to cause haemodynamic changes in 
patients. In particular, as intrathoracic pressure increases during positive-
pressure ventilation (PPV), venous return to the heart is decreased, with a 
subsequent decrease in left ventricular stroke volume57. This decrease in 
stroke volume leads to a decrease in systolic blood pressure.  
Coyle et al first attempted to quantify the decrease in systolic blood 
pressure with PPV in 1983, by calculating the difference between the 
maximum and minimum systolic blood pressures over a single respiratory 
cycle. They called this the ‘positive pressure paradox’ and found that this 
value decreases when fluid is administered to hypovolaemic patients58. 
They also investigated Δ up and Δ down, the differences between the 
baseline (i.e. end-expiratory) systolic blood pressure and maximum and 
minimum systolic blood pressures respectively. Perel et al59 later 
suggested the name ‘systolic pressure variation’ (SPV) in place of Coyle’s 
‘positive pressure paradox’ and investigated this phenomenon more 
formally during graded haemorrhage in dogs. Coyle demonstrated that 
SPV and Δ down rose as cardiac output fell.  
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These studies involved the use of invasive arterial catheters, which apart 
from causing discomfort on insertion, are associated with 
complications60. With the knowledge that the PPG is technically a 
measure of blood volume passing through a specific region over time, 
Partridge et al became the first to describe the use of the PPG to 
measure what they termed ‘pulse waveform variation’ as the maximum 
variation in the peaks of the PPG waveform as measured on printouts of 
the (highly processed) PPG. As the PPG waveform has no units, they 
simply measured the maximum variation in the peaks of the waveform on 
printouts from their monitor and called this ‘pulse waveform variation’. 
They showed that this variation correlated with the SPV in a series of 12 
patients undergoing major surgery61. These findings were confirmed in 
1999 by Shamir et al’s investigation of the relation between SPV and PPG 
variation in a controlled haemodynamic setting62. 
Meanwhile, in the same year a group led by Michard suggested a novel 
dynamic index of volume status based on the arterial waveform called 
‘pulse pressure variation’ (PPV) calculated from the formula:  
PPV (%) = 100 × ((PPmax – PPmin) ⁄ ((PPmax + PPmin) ⁄ 2))  
where PPmax and PPmin were the maximal and minimal pulse pressures 
measured over a respiratory cycle63. They went on to demonstrate that 
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PPV was superior to SPV as an indicator of fluid responsiveness64. 
Monitoring and minimising PPV with an intraoperative fluid management 
protocol was later shown by Lopes et al to result in a decreased length of 
hospital and intensive care unit stay, and reduced rate of complications65. 
In 2005 Cannesson et al published the details of a new method of 
measuring the variation in the pulse oximetry plethysmographic 
waveform (ΔPOP), which was calculated by substituting the equivalent 
terms from the PPG into the formula for PPV. Also known as pulse 
oximetry plethysmographic variation (POPV), this new measure of volume 
status correlated well with PPV in patients with circulatory failure66. 
Unfortunately, as POPV could not be measured automatically the results 
were only available post hoc. Cannesson later became the first to 
investigate “Pleth Variability Index” (PVI), which is a proprietary 
measurement developed by Masimo. Cannesson first evaluated PVI in 
2008, and its calculation derives from the Perfusion Index (PI): 
PI = (AC/DC) x 100 
where AC and DC refer to the varying and fixed portions of light 
absorption respectively.  
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PVI is then calculated using a slight variation on the formula used for 
POPV: 
PVI = ((PImax – PImin) / PImax) x 100 
where PImax and PImin are the maximal and minimal PI recorded over a 
respiratory cycle respectively.  
Cannesson showed that PVI was potentially useful as a measure of POPV 
and correlated well with PPV67. Assuming that the DC portion of the 
signal remains constant over a single respiratory cycle, the only 
difference between POPV and PVI is that they measure percentage 
difference and percentage change respectively. 
Interest in the usefulness of these non-invasive predictors of fluid 
responsiveness has continued with a recent systematic review and meta-
analysis concluding that both methods are reliable predictors of 
responsiveness to fluid boluses of at least 500 mL but are not as useful 
with smaller boluses68. However, none of the included studies were 
randomised-controlled trials, and only 6 studies were included evaluating 
POPV, 3 studies with PVI and one study which looked at both (for a total 
of 233 patients). Further, no children were included, as were few patients 
receiving noradrenaline, which means the results cannot be extrapolated 
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to these groups. The most important weakness of Sandroni’s meta-
analysis, however, is that no clinical outcome data was considered. 
Forget et al have demonstrated reduced lactate levels in patients 
undergoing major abdominal surgery managed with PVI-guided fluid 
administration, but no improved clinical outcomes69. They stated that 
this result confirmed Lopes’ conclusion, which is not correct; reduced 
lactate levels are not the same as reduced lengths of stay or 
complication rates. As with any new medical device technology, 
improved patient outcomes will be the ultimate test of whether POPV or 
PVI has a role in perioperative medicine.  
POPV and PVI have further limitations. As yet there is no commercially 
available automated POPV monitor and consequently it cannot be shown 
whether this measurement would perform better than PVI in improving 
patient outcomes. While they may be helpful in identifying patients who 
will respond to a fluid bolus, they are less helpful in predicting the 
magnitude of response68. As PPV is not helpful as a predictor of fluid 
responsiveness in spontaneously breathing patients70, it is likely that PPG 
will be unhelpful in such patients also. As anyone who has clinical 
experience with pulse oximetry will know, motion artefact can be a major 
drawback with PPG. PVI has been shown lose its ability to discriminate 
between responders and non-responders in patients with a lower 
peripheral perfusion state71. Factors known to affect pulse oximetry such 
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as hypothermia and poor peripheral perfusion72 would also presumably 
interfere with PVI. Given that arrhythmias result in great variation of the 
left ventricular end diastolic volume (and therefore stroke volume) one 
would expect this to interfere with both POPV and PVI. Finally, 
noradrenaline limits the ability of PVI and PPV to predict fluid 
responsiveness in intensive care patients73, which may limit the 
usefulness of PVI in this setting.  
Given that there is no automated POPV device available, it cannot be 
shown whether this measurement would perform better than PVI in 
improving patient outcomes. 
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1.9.Conclusion 
Photoplethysmography has the potential to fulfil new roles in the 
operating theatre. Pulse oximetry was rapidly and widely adopted for 
several reasons; it was reliable, non-invasive, portable, easy to interpret, 
and the treatments for low SpO2 were easy to instigate quickly with 
minimal risk of harm to the patient. Precise accuracy was not as clinically 
important as the trend of the SpO2 in most clinical situations.  
However, the newer applications of PPG may not be adopted into 
routine clinical practice as easily as pulse oximetry, for several reasons. In 
patients undergoing major surgery, the failure to transfuse blood 
appropriately can cause harm to the patient, either in the case of 
omission or over-treatment, and the economic cost may be significant in 
either case. The adverse effects of blood transfusion are well known and 
can include allergic reactions, haemolytic transfusion reactions (from 
donor-recipient mismatch), transfusion-related acute lung injury, 
transfusion-related circulatory overload, bacterial, viral or prion 
contamination and transfusion-related graft-versus-host disease79. 
Introducing non-invasive haemoglobin monitoring into the operating 
theatre has been shown to decrease the usage of donated blood. A 
study conducted in Spain demonstrated a reduction in 20 transfusions 
across 127 patients undergoing hip trauma surgery with non-invasive 
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continuous Hb monitoring, compared with 122 similar patients without 
such Hb monitoring. This amounted to a saving per patient of €20.59, 
which could be extrapolated to a national saving of €1.736 million per 
year were such monitoring to be introduced nationally80. 
Where major bleeding or fluid shifts are anticipated, most anaesthetists 
currently closely monitor Hb via frequent blood sampling (either using a 
blood gas analyser or formal laboratory testing). This raises the question 
of whether or not non-invasive haemoglobinometry can identify patients 
requiring a blood transfusion, in whom timeliness is critical, at an earlier 
stage thus making a real clinical difference. Some benefit in reducing 
blood loss may be expected from the avoidance of repeated blood 
sampling, but in the face of surgical blood losses these gains may be 
clinically insignificant in the operating theatre. In the case of fluid bolus 
administration, PVI does not currently perform well in patients with low 
perfusion states or who are receiving noradrenaline, the very patients in 
whom fluid administration is often most clinically important. Clear and 
reliable reference values will be needed along with a guarantee of 
continuous performance before PPG will be accepted into routine use. 
Due to the limitations described above, these new monitors run the risk 
of becoming just more “noise” in the operating theatre, unless they are 
proven to reliably signal the need for treatment and monitor the 
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response to treatment. More importantly, their use must be 
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Gayat42 2.1 N/A -30.1 34.2 121-142
Pinto43 N/A N/A N/A N/A 111-179
Hadar74 1 8.6 -15.9 17.9 69-139
Kim44 N/A N/A N/A N/A N/A
Belardinelli75 2.9 9.8 -16.4 22.1 N/A
Coquin45 -4 16 -35 43 N/A
Singh76 -6.6 N/A -33.9 20.9 N/A
Mallhi77 3 8.39 -22 28 99-197
Rout78 -8.9 N/A -29.9 12.16 68-203
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2.The Novel Device 
2.1.Introduction 
The University of Limerick, together with the University of Rostock, have 
developed a novel, non-invasive, optical device for the continuous 
measurement of both haemoglobin and stroke volume. The 
measurement of stroke volume could then theoretically be used to 
predict fluid responsiveness. The device relies upon the basic principles 
of photoplethysmography described in the previous chapter. Although it 
has been tested in laboratory conditions and with small numbers of 
patients, it has yet to be validated clinically and exists only in a prototype 
form. Data regarding sensitivity, accuracy or precision of the device have 
not been published by the developers and are not otherwise available. 
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2.2.Description of the device 
The same device was used throughout each of the studies described in 
this work. The measurement part of the device consists of a probe which 
fits over the finger, similar to commercially available pulse oximeters. The 
probe contains three light emitting diodes (LEDs) on the dorsal aspect of 
the finger, and light from these is detected by a photodiode receiver on 
the palmer aspect of the finger. Information from the probe is sent to a 
box (approximately 17 x 10 x 3 cm in dimension) close to the probe. This 
box contains a MSP430 microcontroller (Texas Instruments, Dallas, TX, 
USA) which carries out both time-based control of the LEDs/receiver and 
all signal processing. The purpose of maintaining a short distance 
between the probe and the box is to minimise electrical interference to 
the signals as they pass between each, which can be a source of error. 
The data generated from the signal processing is then sent to a medical-
grade computer via a Universal Serial Bus (USB) cable, and analysed 
using LabVIEW software (National Instruments, Austin, TX, USA). 
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2.3.Haemoglobin measurement 
The three LEDs in the probe emit light at specific wavelengths: 670, 810 
and 1300 nm. 810 nm was chosen as it is very near an isobestic point 
where the absorption coefficients of oxyhaemoglobin and 
deoxyhaemoglobin are identical and therefore their measurement is 
independent of arterial oxygen saturation1. Pure water does not absorb 
much light in the visible spectrum (approximately 380 to 740 nm), but 
absorption increases from about 900 nm upwards. The developers of the 
device chose to measure this absorbance at 1300 nm as a convenient 
way to adjust haemoglobin measurements for variations in water 
content1, 2. The 670 nm wavelength is used in the calculation of arterial 
oxygen saturation only and is not a feature of Hb measurement. A 
standard silicon photodiode, as is normally found in pulse oximeters, 
would only be capable of measuring the absorption coefficients at 670 
and 810 nm, so an indium-gallium-arsenide photodiode3 is instead used 
to measure at all three wavelengths as it has a spectral range of 
400-1700 nm. Assumptions are made that red blood cells consist mostly 
of water, and that plasma mostly contains water. Of course, these 
assumptions over-simplify the situation, and are potential sources of 
error. The software calculates the “ratio of ratios” of absorbances at 810 
and 1300 nm in the varying and non-varying components of the PPG 
waveform, and this number can then be transformed to display the Hb 
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using the device’s calibration curves. The Hb displayed on the screen 
represents a 50-point moving average. 
In an initial study, the developers of the device examined the 
absorbances of artificially varying haemoglobin concentration in a closed 
cardiopulmonary bypass circuit (using donor blood, and with no patient 
involved). Over a range of haemoglobin concentrations of 50-206 g.l-1, 
and partial least squares regression calibration, they found the device to 
be accurate1. They carried out further calibration using just 27 
volunteers, whose haemoglobin concentrations were also measured 
using a HemoCue (HemoCue, Ängelholm, Sweden), and the resulting 
calibration curves were validated using 15 more volunteers. There is no 
information as to the range of haemoglobin concentration among the 
initial 27 subjects. Reading from the published Bland-Altman plot 
relating to the validation exercise with the subsequent 15 volunteers, the 
range among the volunteers appears to have been 117.6-166 g.l-1, which 
falls broadly in the normal range. Two major flaws with this study were 
that the initial measurements were taken from pulseless flow, which may 
lead to errors of calculation of absorption as there is then no varying part 
of the PPG signal, and that the donated blood used in the flow circuit 
contained no “plasma, proteins, leukocytes or thrombocytes”. 
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2.4.Stroke volume measurement 
For measurement of stroke volume, the 810 nm wavelength is used to 
plot the PPG waveform. The area under the varying part of the resulting 
curve is calculated using integration (an adaptive variant of the Gauss-
Lobatto quadrature4). The developers term this area ‘stroke volume’ (SV) 
although strictly speaking this is not correct. From this they calculate 
stroke volume variation (SVV) as: 
SVV (%) = (SVmax – SVmin) / SVmean 
where SVmax and SVmin are the maximal and minimal values of SV 
respectively over a complete respiratory cycle. SVmean is the mean of all 
measurements of SV across the same respiratory cycle5. Rising velocity 
(RV) is also calculated as the ratio of the maximal amplitude of systole 
over its duration. It is not made clear as to how these values are then 
used to arrive at a single calculation. Values are calculated every cardiac 
cycle and a mean value is displayed every six seconds. This mean 
represents a 25-point moving average. In these initial studies, the device 
required initial calibration in each patient, using another method of 
measurement for cardiac output or stroke volume. For the purposes of 
our study, only the raw output of the device was considered for statistical 
analysis to attempt to establish correlation. 
58
In the first report of monitoring patients using this function of the device, 
patients from intensive care units undergoing monitoring using either 
transpulmonary thermodilution via a pulmonary artery catheter (PAC), or 
the less invasive PiCCO system (Pulsion Ltd, Munich, Germany) had their 
stroke volumes compared to the output from the new device. They do 
not specify how many patients were studied or how many patients had 
PAC versus PiCCO monitoring, nor do they publish any demographic 
data relating to these patients. No attempt at summarising the results is 
made. It is difficult to draw any conclusions from this paper, other than 
from one graph representing an “unstable” patient where the device 
suggested the patient required treatment with a bolus of intravenous 
fluid (as a greater than 20% drop in SV over 22 minutes was evident), 
whilst at the same moment PiCCO demonstrated that SV had in fact 
fallen by just 5.2%, and would not therefore require intervention6. 
Of note, in this and a further study5 there was no distinction made 
between ventilated and non-ventilated patients which would be 
expected to have a dramatic change on results, as it is well known that 
positive pressure ventilation is required to induce useful and measurable 
variation in the PPG waveform (see section 1.9, Pulse oximetry 
plethysmographic variation and Plethysmographic Variability Index as 
monitors of fluid responsiveness). 
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2.5.Differences between the novel device and similar 
available devices 
As described in the introduction, there are two other devices already 
commercially available which can measure haemoglobin non-invasively. 
Masimo Corporation’s (Irvine, California, USA) two devices, the Radical-7 
and the Pronto-7 consists of a finger clip type probe with light emitting 
diodes and photodiode receivers. Single-use probes for use on various 
sites (fingers, toes) are available, along with an ear probe. The details of 
wavelengths, materials and algorithms used are not available. Unlike the 
novel device, the probes connect directly to a proprietary display via a 
non-universal cable. Apart from haemoglobin, the device can also 
measure carboxyhaemoglobin, methaemoglobin, oxygen saturation and 
measurements Masimo terms “oxygen content” and “acoustic 
respiratory rate”. The Radical-7’s display is designed for continuous 
monitoring purposes, such as during anaesthesia, while the Pronto-7 is 
smaller and designed to be portable for use on a ward or in clinics. The 
basic technology in each is otherwise similar. 
The manufacturers publish minimal information regarding error rate and 
performance in hypoperfusion states. There are a small number of 
studies investigating the device’s performance in hypoperfusion states. 
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Two studies found that the Radical-7 performed well as an oximeter in 
low perfusion states but did not specifically test the haemoglobinometry 
function6, 7. A further two studies found good performance of 
haemoglobinometry at low perfusion states8, 9, but one study found that 
the correlation between the Masimo device and a laboratory test for 
haemoglobin was best in patients with a normal perfusion state and so 
may not perform as well in a lower perfusion state10. 
Regarding the novel device, no information regarding error rate, 
performance in hypoperfusion states or data pairing in non-critically low 
haemoglobin states was known prior to the commencement of the 
studies included in this thesis. 
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Measuring haemoglobin usually requires sampling and processing of 
blood. In this study, we undertook the first clinical evaluation of a novel, 
non-invasive device for the continuous measurement of plasma 
haemoglobin concentration. 
Methods 
We enrolled twenty five patients undergoing elective cardiac surgery. At 
four pre-determined intervals, samples of blood were taken for plasma 
haemoglobin estimation on a blood gas analyser and a laboratory device 
and were compared with the plasma haemoglobin estimation on the 
novel device using the Bland-Altman method. 
Results 
The 95% limits of agreement for estimation of plasma haemoglobin in 
the cases of the device versus laboratory, the device versus the blood 
gas analyser and the blood gas analyser versus the laboratory were 101.3 
g.l-1, 103.1 g.l-1 and 14.5 g.l-1 respectively. The bias (mean difference) in 
each case was 27.4 g.l-1, 25.1 g.l-1 and 2.4 g.l-1 respectively.  
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Conclusions 
We conclude that the novel device in its current form is not a suitable 
replacement for more invasive methods of determining plasma 
haemoglobin in patients in the setting of cardiac surgery. However, 




In many clinical situations (such as during cardiac, vascular surgery or 
following trauma), plasma haemoglobin concentration is measured 
frequently and/or urgently. Currently, this requires sampling and 
processing of blood, either with a formal laboratory full blood count, with 
a blood gas analyser, or with a point-of-care device. A continuous, non-
invasive and accurate method would allow for more rapid decision 
making in such situations.  
The Optical Fibre Sensor Research Centre at the University of Limerick 
together with the Institute of General Electrical Engineering at the 
University of Rostock, Germany have co-developed a novel device for 
the non-invasive, optical, real-time measurement of haemoglobin, which 
calculates a ratio of the absorbances of different wavelengths of light 
passed through a fingertip to estimate haemoglobin, in a similar manner 
to a standard pulse oximeter1. Masimo Corporation has previously 
gained FDA approval for a non-invasive pulse haemoglobinometer (the 
Radical-7 pulse CO-oximeter) and several studies have evaluated its 
accuracy2-6. This device uses multiple wavelengths of light to determine 
haemoglobin, (although the wavelengths employed have not been 
published). The device which is the subject of this investigation utilises 
just two wavelengths of light which would lower the cost of production, 
67
and much of the signal processing takes place within the finger probe 
itself to minimise interference. Differences and similarities between the 
novel device and the Radical-7 are listed in Table 1. 
During cardiopulmonary bypass, patients can undergo large and rapid 
changes in haemoglobin secondary to blood loss, fluid administration, or 
blood product transfusion. In addition, the institution of cardiopulmonary 
bypass results in haemodilution, and accordingly these cases present an 
ideal opportunity to study a wider range of haemoglobin within the 
population group. The primary objective of this study was to compare 
haemoglobin estimation using the novel device with a standard 
laboratory device (XE-2100, Sysmex Corporation, Kobe, Japan). The 
secondary objectives were to compare results from the novel device with 
a blood gas analyser (GEM Premier 4000, Instrumentation Laboratory, 
Bedford, MA, USA) and finally to compare results from the standard 
laboratory device with those from the blood gas analyser. 
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3.3.Methods 
With institutional ethical committee approval (Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, 21/10/2010) and having 
obtained written informed consent from each, 25 American Society of 
Anesthesiology (ASA) grade III patients scheduled for elective cardiac 
surgery requiring cardiopulmonary bypass were studied. Exclusion 
criteria were the presence of any known haemoglobinopathy or recent 
dye or contrast studies as these may interfere with the measurement of 
haemoglobin, or the intra-operative use of an intra-aortic balloon pump 
as this would significantly alter the contour of the plethysmographic 
waveform and prevent correct functioning of the device. 
Each patient’s age, gender, height, weight, body mass index, baseline 
haemoglobin and temperature (via a nasal temperature probe) were 
recorded. In addition, each patient’s smoking history was recorded. 
Following induction of anaesthesia, the novel device was fitted on the 
index finger of each patient’s right hand (unless the right radial artery was 
to be used for grafting, in which case the left index finger was used). 
Blood was drawn from the arterial catheter via the port closest to the 
patient at four standard time points using the following technique. 
Initially 10 ml blood/heparinised saline was drawn from the arterial 
catheter. Subsequently 6 ml of arterial blood was drawn (in a second 
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syringe) and 4.1 ml of this blood was transferred to a standard Lithium-
Heparin blood sample bottle and sent to the haematology laboratory for 
haemoglobin estimation using the hospital’s standard CO-oximeter 
(XE-2100, Sysmex Corporation, Kobe, Japan) for analysis. The remaining 
blood from this syringe was then transferred to an arterial blood gas 
syringe, and processed using the GEM Premier 4000 blood gas analyser. 
The original 10 ml of blood/heparinised saline was then returned to the 
patient to minimise unnecessary blood loss. To determine haemoglobin, 
the device first calculated a coefficient from the measured absorbances 
of two wavelengths of light through the varying part of the pulse signal, 
similar to the method used in standard clinical pulse oximeters. The 
device then referred this coefficient to a lookup table and displayed the 
result on-screen as haemoglobin. This initial haemoglobin determination 
served as an additional calibration for further measurements within the 
same patient. At each time point, the patient’s haemoglobin as displayed 
by the novel device was recorded, and an on-screen button was pressed 
which recorded the 50-point moving average of the haemoglobin 
coefficient at that time (i.e. the average of the most recently acquired 50 
haemoglobin coefficients). The four time points selected were, (i) skin 
incision, (ii) two minutes after completion of administration of the first 
dose of heparin (pre-bypass), (iii) two minutes after completion of the first 
dose of protamine (post-bypass) and (iv) at completion of the final skin 
suture (at the end of surgery). We chose a study sample size (25 subjects) 
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arbitrarily to generate 100 paired samples across the four time points for 
each comparison. Scatter plots were constructed and a line of equality 
was included on each plot for the each following comparisons (i) device 
haemoglobin vs. full blood count haemoglobin (the primary outcome), (ii) 
device haemoglobin vs. blood gas analyser haemoglobin and (iii) blood 
gas analyser haemoglobin vs. full blood count haemoglobin. The 
laboratory device was considered the ‘gold standard’ for comparing the 
methods of measurement. The blood gas analyser was selected for 
comparison on the basis that anaesthetists commonly utilise this device 
to measure haemoglobin intraoperatively as a time-saving measure 
rather than sending a sample to the laboratory. The final comparison, 
between the blood gas analyser and the laboratory device was carried 
out as previously the limits of agreement between these have been 
found to be quite wide7. Stata Statistical Software: Release 13 (StataCorp 
LP, College Station, TX, USA) was used for these, and also to construct 
Bland-Altman8 plots for each comparison. The method proposed by 
Bland and Altman9 for the calculation of bias and limits of agreement was 
applied using MedCalc (MedCalc Software, Ostend, Belgium), as this 
study required repeated measurements of haemoglobin within the same 
subjects in a situation where the true value of haemoglobin was varying. 
Statistical analysis included descriptive statistics and tests of equality of 
variances across the range of patient means (Spearman’s Rho), an 
assumption required for Bland-Altman analyses. 
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3.4.Results 
Twenty-five patients were enrolled in the study. Patient characteristics, 
baseline haemoglobin and the planned surgical procedure are 
summarised in Table 2. On two occasions during the study, no samples 
were recorded across all three modalities due to observer omission. Of 
the remaining 98 sets, one sample processed with the blood gas 
analyser was not recorded, again due to observer omission. Two further 
laboratory full blood count samples were not recorded due to breaches 
of protocol (one was not taken, the other not processed) leaving 95 
complete sets of paired data for analysis.  
Fifteen patients had never smoked and one patient was an active smoker 
of 84 pack years. Nine patients were former smokers whose cessation 
dates ranged from six weeks to 61 years prior to surgery. The active and 
former smokers had a mean of 28.3 pack years. In the early part of the 
study period we encountered six instances (in the first seven participants) 
of “freezing” of the on-screen display of haemoglobin, requiring a 
system reboot between sample points. The problem was found to be 
due to a software bug, which was corrected by the developers before 
enrolment of the eighth participant; the problem recurred on only one 
further occasion (the last participant).  
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The assumption that the within-subject variance was the same for all 
subjects was reasonable, as low values of Spearman’s Rho showed that 
there was no evidence of a relationship between variability of the 
differences and the average of the two measurements. The results of the 
Bland-Altman analysis including the mean differences, 95% limits of 
agreement and Spearman’s Rank Order correlation values for each 
comparison are summarised in Table 3. Bland-Altman plots and scatter 
plots are shown in Figure 1.  
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3.5.Discussion  
Our results show that, in its current form the novel device studied is not a 
suitable replacement for invasive methods of determining haemoglobin 
in patients in the setting of cardiac surgery. The 95% limits of agreement 
in the cases of the device versus the laboratory full blood count and the 
device versus the blood gas analyser demonstrate a very broad range in 
the reference interval (101.3 and 103 g.l-1 respectively), which would be 
clinically unacceptable. The 95% limits of agreement for the blood gas 
analyser versus full blood count show a much closer agreement (a range 
of 14.5 g.l-1) and a far lesser mean difference, indicating that these two 
methods are likely to be interchangeable. Graphs of haemoglobin 
measured by the novel device versus those measured by the laboratory 
full blood count and the blood gas analyser show a large scatter about 
the line of equality in comparison with the blood gas analyser versus full 
blood count (Figure 1). We did not compare the novel device with other 
non-invasive haemoglobin measurement devices such as Masimo’s 
Radical-7 as the novel device has not yet been clinically validated or 
compared to a gold standard. 
Previous studies of non-invasive haemoglobin monitors have reported 
varying degrees of agreement with traditional methods. In their study 
analysing 335 paired measurements comprising 20 healthy volunteers 
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who underwent haemodilution (i.e. where the true haemoglobin value 
varied), Macknet et al2 found a non-invasive pulse haemoglobinometer 
(Masimo Radical-7, Masimo Corporation, Irvine, CA, USA) and their 
reference method to have a mean difference of -1.5 g.l-1 and that the 
difference between methods was <20 g.l-1 for 97% of the measurements. 
Dewhirst et al3 using Masimo’s Radical-7 and a point-of-care analyser in 
children found the mean difference to be 1 g.l-1 and that 80% of sample 
sets were within 20 g.l-1. They concluded that the non-invasive device 
was valuable as a continuous trend monitor, but unacceptable to base 
transfusion decisions upon. This was a similar conclusion to that of Park 
et al4 in their study of the Radical-7 in children undergoing neurosurgery. 
However, Nguyen et al5 noted a poor correlation between the Radical-7 
and laboratory full blood count in 41 patients following cardiac surgery 
and, in particular, noted that the difference between sampling methods 
varied considerably in repeated samples from the same patient at the 
same time (between -63 and +12 g.l-1 for one patient). Together these 
findings show that this method of non-invasive measurement of 
haemoglobin has some promise but is, as yet, unsuitable for use in the 
clinical setting of cardiac surgery. 
The close level of agreement between the GEM Premier 4000 blood gas 
analyser and the laboratory full blood count has not been shown before 
and is clinically relevant as many cardiac surgical centres now rely on 
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similar analysers for the rapid assessment of haemoglobin. An alternative 
point-of-care device has previously been shown to be a valid method in 
the setting of critical care10. 
There are several potential sources of error with this device that might 
explain the poor level of agreement with more established methods for 
measuring haemoglobin. First, the data used to calibrate the device were 
obtained from a relatively small (n=27) sample of healthy volunteers 
which were compared to the HemoCue (HemoCue, Ängelholm, Sweden) 
device1. Due to the small sample size, any the effect of any error with 
readings would be greatly amplified. Also, the HemoCue is a portable 
point-of-care device which could not be considered a ‘gold standard’. 
Second, as subsequent within-patient estimations of haemoglobin relied 
in part on the initial reading, drift is likely to have occurred leading to 
increasingly inaccurate estimations. During bypass (between time points 
two and three in each case), the device would have lost all data 
acquisition due to the lack of a pulsatile signal, which may have 
exaggerated any drift present. Third, the patient group studied 
presented specific challenges that potentially lead to problems with 
signal acquisition. (i) Patients undergoing cardiac surgery are more likely 
to have lower perfusion states than healthier patients. (ii) Patients with 
moderate and severe congestive heart failure have increased stiffness 
and decreased compliance of the brachial arteries11. (iii) Hypothermia 
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alters vasomotor tone, which is of particular concern in patients following 
cessation of cardiopulmonary bypass. (iv) Cardiopulmonary bypass itself 
elicits an inflammatory response, which can lead to alterations in 
vasomotor tone. A further analysis of our data showed that the mean 
difference of the device haemoglobin and the full blood count 
haemoglobin before cardiopulmonary bypass was 17.4 g.l-1, while the 
mean difference was 37.4 g.l-1 following cardiopulmonary bypass. This is 
likely due to a combination of drift as described, inflammatory effects of 
cardiopulmonary bypass, patient hypothermia following bypass and the 
use of vasoactive agents (which were not recorded as part of this study). 
Fourth, the presence of carboxyhaemoglobin and methaemoglobin may 
lead to inaccuracies in the estimation of haemoglobin. This is a potential 
confounder with any estimation of haemoglobin where 
carboxyhaemoglobin and methaemoglobin concentrations are not 
measured and then subtracted from the estimated haemoglobin. Our 
study was not designed to take this into account. Fifth, following 
completion of the study, the continuously recorded data from the novel 
device were analysed to retrieve the haemoglobin coefficient at each 
sample point. It was discovered that on 52 of the 100 data points the 
signal detected by the novel device was of such a poor quality that 
measurements could not be obtained and therefore the haemoglobin 
coefficient could not be determined. This led us to conclude that the 
haemoglobin calculated by the device for each of these time points is 
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likely to be inaccurate. Despite this, when these data points were 
excluded, the mean difference of the device haemoglobin and the full 
blood count haemoglobin was actually worse at 29.2 g.l-1. Sixth, the 
software issues that lead to the device freezing in the earlier part of the 
study, as previously mentioned, may have further contributed to the loss 
of calibration in the subsequent samples in the affected patients. 
Improvements could be made to the signal processing algorithms within 
the device, which might lead to less error in lower perfusion states or 
with changes in vasomotor tone. Calibrating the device empirically using 
a far larger group of volunteers, such as the thousands of volunteers 
used to calibrate standard commercial pulse oximeters would likely 
increase the accuracy of this device. Revision of the software to ensure 
that further freezing does not occur during device operation could also 
prevent intra-patient calibration problems. Results could also be 
improved using the simple method proposed by Miyashita et al whereby 
the difference between the haemoglobin reading from the device and a 
laboratory or point-of-care value is used to adjust subsequent readings 
on the device (within the same patient)12. This method improved the 
accuracy of non-invasive haemoglobin measurement in 17 patients (with 
71 measurements), but only included those undergoing abdominal 
surgery. Of course, the device could not then be truly described as ‘non-
invasive’. 
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There are limitations to our study. First, the precision of our gold 
standard was not established at each sample point. This would have 
required as much as three times the volume of blood to be withdrawn 
from each patient at each time point, which we deemed unacceptable. 
Second, the acceptable 95% limits of agreement were not stated a priori, 
although the calculated limits of agreement were so wide as to make 
clear that the device would not be clinically useful at this point. Finally, 
the investigators were not blinded to the output from the device or the 
results from the blood gas analyser.  
Finally, details of each participant’s smoking history were recorded as at 
the time of design of the study’s protocol it was thought that the 
presence of carboxyhaemoglobin may have prove to be a source of 
interference to the measurement of haemoglobin. However, no research 
has been published to date which indicates that this may be the case. 
Our results indicate that, in its current form, the novel device studied is 
not suitable for clinical use; several technical challenges (outlined above) 
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3.6.Tables 
Table 1. Similarities and differences between the novel device and the 
Radical-7 (Masimo Corporation). 
Novel Device Radical-7
Measures O2 saturations and Hb 
only
Measures heart rate, O2 
saturations, Hb, COHb, MetHb, 
Pleth Variability Index
Clip-type finger probe only Clip-type probe which can be used 
on fingers or toes, ear probe also 
available
2 wavelengths (810 and 1300 nm) Multiple wavelengths (details not 
published)
Signal processing close to the 
probe
Signal processing in the display 
unit
Display unit not compatible with 
existing intraoperative monitoring 
systems
Display unit compatible with a 
range of intraoperative monitoring 
systems
Calibrated using 27 volunteers Calibration data unavailable
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Table 2. Summary of patients' characteristics and type of surgery. Values 
are number, median (IQR [range]) or number (proportion). 
Number of subjects 25
Age; years 67 (57-74 [34-80])
Sex; M: F 9 : 16
Height; cm 165 (160-172 [152-184])
Weight; kg 80 (68-90 [51-147])
Body mass index; kg.m-2 27.9 (24.1-31.3 [20.6-56.9])
Baseline [Hb]; g.l-1 133 (124-146 [110-163])
Baseline temperature; °C 36.2 (36-36.5 [36-37])
CABG 12 (48%)
Valvular surgery 9 (36%)
Combined (CABG and valvular) 
surgery
3 (12%)
Atrial myxoma 1 (4%)
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IQR=Interquartile range 
[Hb]=plasma haemoglobin concentration 
CABG=Coronary artery bypass graft 
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Table 3. Comparison between the three study methods of plasma 
haemoglobin estimation. Values are mean [upper, lower 95% limits of 
agreement] and number (significance level).  
[Hb]=plasma haemoglobin concentration  
FBC=full blood count  
BGA=blood gas analyser 
†Calculation is based on standard deviation of differences between two 
methods vs. average of two methods per subject 
Method 
Comparison 











-0.01 (0.97) 0.02 (0.92) -0.05 (0.81)
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3.7.Figures 
Figure 1 (following page). (a) Bland-Altman plots and (b) scatter plots for 
the comparisons between each method of plasma haemoglobin (Hb) 
estimation: the novel device, laboratory full blood count (FBC) and the 
blood gas analyser (BGA). The solid horizontal line in each Bland-Altman 
plot indicates the mean difference (bias) between methods; the broken 
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Appropriate diagnosis and treatment of anaemia in pregnant women 
usually requires sampling and processing of blood. Accurate and non-
invasive measurement of haemoglobin would make this much easier and 
potentially lead to cost-savings with improved outcomes. In this study we 
compared haemoglobin measurement using a non-invasive novel device 
with a laboratory standard.  
Methods 
We compared the routinely measured haemoglobin from one hundred 
women attending their twenty-week antenatal check with that of the 
novel device using scatter and Bland-Altman plots. 
Results 
The mean difference of haemoglobin concentration between the 
methods was 10.4 g.l-1, with a standard deviation of 19.8 g.l-1. The 95% 
limits of agreement were -28.4 to 49.1 g.l-1. The coefficient of 
determination (r2) between the two methods was 0.00018769. A 
measurement error occurred whereby the device was not reset correctly 
between measurements which may have lead to inaccurate results. 
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Conclusions 
The novel device is not an acceptable method of haemoglobin 
concentration measurement in pregnant women at present. We 
document possible refinements which may lead to greater accuracy in 
this novel device in future studies. The measurement error means that 
our results should be interpreted with caution. 
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4.2.Introduction  
Plasma haemoglobin concentration is a frequently performed blood test 
in all areas of healthcare. This usually requires venepuncture (with 
inherent discomfort), sampling and processing of blood, either in the 
laboratory as a formal Full Blood Count (FBC), or with a point-of-care 
analyser. In the case of a laboratory FBC, an urgently required result may 
not be obtainable by the clinician in a timely manner. A reliable, non-
invasive, point-of-care device would allow for painless and rapid 
haemoglobin estimation, while potentially decreasing the cost of 
processing blood samples. Such a device would be useful in clinical 
circumstances where haemoglobin concentrations are rapidly changing 
or need to be monitored closely, such as pregnancy, trauma, or cardiac 
surgery. 
The World Health Organization reports that 18% of pregnant women 
from industrialised countries have iron-deficiency anaemia1, and 
consequently pregnant patients attending antenatal clinics frequently 
undergo blood sampling for haemoglobin estimation. At present, all 
pregnant women booked into Cork University Maternity Hospital have a 
FBC taken at the 20-week antenatal check. Most of these women also 
have a FBC taken by their general practitioner prior to booking, and all 
those considered to be at risk of anaemia will have subsequent frequent 
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blood sampling. Earlier and more frequent measurement of 
haemoglobin may allow for more timely iron supplementation, as well as 
the ongoing measurement of efficacy of treatment in those found to 
require iron supplementation. 
Recently, photoplethysmography (PPG) has been used for the non-
invasive measurement of haemoglobin concentration, in a similar manner 
to pulse oximetry. Masimo Corporation (Irvine, CA, USA) currently 
produce two devices utilising this technology; Radical-7™ and 
Pronto-7™. These devices have been tested clinically and were the 
subject of a recent systematic review and meta-analysis2. Masimo’s 
devices use seven wavelengths of light, the precise values of which are 
protected under patent. Another device, manufactured by OrSense (Nes 
Ziona, Israel), the NBM-200™, uses occlusion PPG to provide an 
intermittent estimation of haemoglobin concentration. The Optical Fibre 
Sensor Research Centre at the University of Limerick together with the 
Institute of General Electrical Engineering at the University of Rostock, 
Germany have co-developed a different novel device for the non-
invasive, optical, real-time measurement of haemoglobin, which also 
makes use of PPG3. In contrast to Masimo’s device, the novel device uses 
just two wavelengths of infrared light/near-infrared light, which has a 
potential cost saving. This device has also been shown to accurately 
measure very low haemoglobin concentrations in-vitro (38.7 g.l-1)4. An 
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initial investigation of the device (in the setting of cardiac surgery with 
multiple within-subject sampling) demonstrated poor correlation with 
laboratory FBCs and a blood-gas analyser, particularly in the period 
following cessation of cardiopulmonary bypass. This was due to several 
factors, many of which were unique to that setting5. However, the device 
has not been tested in the setting of single patient samples at an 
antenatal clinic until now. There was no opportunity to make 
improvements to the device, as this study and the previous one ran 
simultaneously. The similarities and differences between these three 
devices are summarised in Table 1. 
The primary objective of this study was to compare Hb estimation using 
the novel device with standard laboratory measurement (XE-2100 
Sysmex Corp., Kobe, Japan), in pregnant patients presenting for their 
20-week antenatal check. 
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4.3.Methods 
With institutional ethical committee approval (Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, 30/05/2011) and having 
obtained written consent from each, 100 adult females attending the 
antenatal clinic of Cork University Maternity Hospital for their 20 weeks’ 
gestation check who were due for routine FBC were enrolled in this 
prospective observational study. It is routine practice at this institution to 
recommend all women undergo a FBC at this stage of gestation. 
Exclusion criteria were the presence of any known haemoglobinopathy, 
recent dye or contrast studies, or the presence of acrylic nail polish/
coverings, all of which would potentially interfere with the absorption of 
light from the device. 
Each participant’s age, height, weight, body mass index (BMI) and 
smoking status (with smoking history as appropriate) were recorded. The 
novel device was placed on the index finger of the opposite upper limb 
to that used for blood sampling. This avoided any interference from the 
tourniquet with light absorption by the device. In each case the device 
was left in place for one minute to allow its reading to stabilise. As a 
venous blood sample was drawn, the haemoglobin concentration 
measured by the device was recorded. The blood sample was sent to the 
hospital’s haematology laboratory for analysis using the hospital’s CO-
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Oximeter (XE-2100, Sysmex Corporation, Kobe, Japan) and this 
measurement of haemoglobin concentration was subsequently recorded. 
The investigators were blinded to the results of the laboratory FBCs until 
after the final participant had been enrolled and recorded. 
To determine plasma haemoglobin concentration, the device first 
calculates a coefficient from the measured absorbances of two 
wavelengths of light through the varying part of the pulse signal, similar 
to the method used in standard clinical pulse oximeters. The device then 
refers this coefficient to a reference table and displays the result on-
screen as haemoglobin concentration. This initial haemoglobin 
determination serves as a further calibration for further measurements 
within the same patient. At the time of sampling, the patient’s 
haemoglobin as displayed by the novel device was recorded, and an on-
screen button was clicked which recorded the 50-point moving average 
of the haemoglobin coefficient at that time (i.e. the average of the most 
recently acquired 50 haemoglobin coefficients). All data were recorded 
on case record forms and subsequently entered into an Excel 
spreadsheet (Microsoft, Redmond, WA, USA). A scatterplot comparing 
novel device haemoglobin concentration and laboratory haemoglobin 
concentration was constructed, and a line of equality added. The 
coefficient of determination (r2) was calculated for the comparison, and a 
Bland-Altman6 plot of the mean versus the difference in haemoglobin 
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concentration for each pair was produced. Stata Statistical Software: 




100 patients were enrolled in the study. Patient characteristics are 
summarised in Table 2. In one case, the height and weight were not 
recorded, although the patient’s BMI was. Median haemoglobin 
concentration was 117 g.l-1. Participant’s smoking status is summarised in 
Table 3. Of the active smokers, the mean number of cigarettes per day 
smoked was 6 (range 2 to 10). Of those who had previously smoked, the 
mean time since cessation was 4.12 years (range 0.29 to 16) and the 
mean number of cigarettes per day smoked was 8.71 (range 1 to 20).  
A scatter plot with line of regression and a Bland-Altman plot are shown 
in Figures 1 and 2 respectively. The coefficient of determination (r2) 
between the two methods was 0.00018769. The mean difference (bias) 
of haemoglobin concentration between the methods was 10.4 g.l-1, with 
a standard deviation of the bias (accuracy) of 19.8 g.l-1. The 95% limits of 




Our results show that the novel device is not currently suitable as a 
replacement for more invasive methods of haemoglobin concentration 
estimation in the setting of antenatal patients of approximately 20 weeks’ 
gestation. The poor correlation and broad range of the 95% limits of 
agreement (up to 77.5 g.l-1) would not be clinically useful in the diagnosis 
and management of maternal anaemia. 
Few studies have investigated the use of non-invasive haemoglobin 
concentration estimation in the pregnant population. Butwick et al 
compared Masimo’s Radical-7 with laboratory measurements in patients 
before and after caesarean section delivery and found a significant 
positive bias at baseline (12.2 g.l-1) and broad limits of agreement (-9 to 
33.3 g.l-1) concluding that the device was not useful for clinical purposes 
in this setting7. This was confirmed in a similar study by Skelton et al 
which found the overall limits of agreement for the Radical-7 were -42 to 
20.2 g.l-1 and that it gave lower and less accurate readings than the 
HemoCue (HemoCue, Ängelholm, Sweden)8. An investigation of non-
invasive haemoglobin monitoring in pregnant patients carried out using 
the NBM-200 (OrSense, Nes Ziona, Israel) found a bias of 1 g.l-1 with 
narrower 95% limits of agreement (-15.9 to 17.9 g.l-1) than our study9. 
Crowley et al investigated the use of Masimo’s Rad-87 device to detect 
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anaemia in a population sample that included (but was not exclusive to) 
pregnant women. They did not report bias, precision or limits of 
agreement, but did note that the Pearson correlation coefficient was 
r=0.59 between the device and invasive haemoglobin concentration 
estimation, and found that the device had a 90% and 92% sensitivity in 
detecting true haemoglobin less than 120 and 130 g.l-1 respectively10. 
Notwithstanding the results of these studies, we felt that there was 
equipoise as to whether the novel device would perform better than 
other devices due to its differing method of measurement (the NBM-200 
being based on occlusion spectroscopy, and the Radical-7 using 
unknown wavelengths).  
Our wide limits of agreement are consistent with these studies’ findings. 
A recent systematic review and meta-analysis of non-invasive 
haemoglobin measurement devices concluded that limits of agreement 
were still quite broad despite a low bias, generally meaning that 
clinicians should exercise caution when using output from these devices 
to inform decisions regarding blood transfusion2. Of note, the authors of 
that review included only 6 of the 32 identified studies in their analysis, 
suggesting heterogeneity between studies and their protocols. 
Previously, Rice et al specifically reviewed the Radical 7 device and also 
concluded that published studies indicated that the device should not be 
used to determine the need for blood transfusion11. In our study, the bias 
101
of 10.4 g.l-1 indicated a tendency for the device to overestimate 
haemoglobin. The most significant example of this was a woman whose 
haemoglobin concentration was estimated as 111 g.l-1 by the novel 
device, but whose formal laboratory measured haemoglobin 
concentration was only 75 g.l-1. It is likely that the novel device would 
have failed to identify the severity of this patient’s anaemia.  
There are several reasons as to the poor level of agreement between the 
novel device and the laboratory FBC. First, it was discovered following 
completion of the study that the device had not been reset between 
each individual patient’s haemoglobin measurement. As subsequent 
estimations of haemoglobin concentration (on subsequent patients) were 
self-calibrated against the initial reading, the reported value of 
haemoglobin would inevitably drift from the “true” value resulting in 
further inaccuracy. This was a major error in the conduct of the study and 
consequently all conclusions should be viewed with caution. Second, the 
device was calibrated using the data from a small sample of healthy 
volunteers (n=27)3. This narrow pool of probable homogenous data 
could lead to variations in estimating haemoglobin concentration from 
any measured haemoglobin coefficient. Third, our study was not 
designed to take into account the potential inaccuracies caused by the 
presence of carboxyhaemoglobin (COHb) and methaemoglobin. The 
smoking history of each participant was recorded, and indicated that 
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11% of participants were active smokers at the time of enrolment. 
However, as COHb levels were not measured, the knowledge that 11% 
of participants were active smokers can provide a guide only as the 
potential influence of COHb on the results. The bias for active smokers 
was 12.9 g.l-1 with narrower limits of agreement (-14.2 to 40 g.l-1) than for 
the study group as a whole, suggesting that the device performed 
marginally better in active smokers, although the sample size is too small 
to draw any conclusion. Finally, previous analysis of the 
plethysmographic pulse waveform in pregnant versus non-pregnant 
women found that the total power of pulse was lower in pregnant 
women, and particularly so in the second trimester12. The implications of 
this for our study are not clear, but it indicates plethysmographic 
differences between pregnant and non-pregnant subjects, which are not 
accounted for in the novel device. 
Miyashita et al13 have shown that simple refinements of the software 
algorithm can narrow the 95% limits of agreement of non-invasive 
haemoglobinometers. Masimo have introduced a similar modification to 
their devices (yet to receive FDA approval) which has also improved 95% 
limits of agreement14. It is reasonable to suggest that further refinements 
to the algorithms of the novel device will lead to more accurate 
haemoglobin concentration estimation. Improvements to filtering and 
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larger-scale calibration (with thousands of patients) could also be 
expected to improve the device’s performance. 
There are several limitations to our study. First, despite including 99 
samples, this study is small and would require larger numbers to provide 
a more thorough clinical evaluation. Second, the novel device’s 
estimation of haemoglobin concentration was not compared with the 
gold standard for haemoglobin measurement, the cyanmethaemoglobin 
method. Third, we did not define acceptable 95% limits of agreement a 
priori, although the actual limits of agreement were wide enough to 
indicate that the device is not currently acceptable for clinical use.  
Although not a goal of this study, we found that 11% of participants in 
this study were active smokers at approximately 20 weeks’ gestation. 
Although alarming considering the well-known harmful effects of 
antenatal smoking15, this represents a lower incidence than that shown 
by a previous survey (in 2010) of maternal smoking patterns in Ireland, 
where the incidence was 23.5%16. A larger sample size would be 
required to establish a more accurate incidence, but may represent 
changing patterns in smoking in pregnant women in Ireland. 
Our results show that the novel device is not an acceptable substitute for 
more established methods of haemoglobin concentration measurement 
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in pregnant women. Improved calibration using several thousand 
patients, together with refinements of the processing algorithms may 
lead to more accurate measurements of haemoglobin concentration with 
this novel device in future studies. The failure to reset the device 
correctly between measurements means that our conclusions should be 
viewed with caution. 
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4.6.Tables 
Table 1. Similarities and differences between the novel device, the 
Radical-7 (Masimo Corporation) and NBM-200 (OrSense). 
Novel Device Radical-7 NBM-200
Continuous readings Continuous readings Intermittent readings
Measures O2 
saturations and Hb 
only
Measures heart rate, 
O2 saturations, Hb, 
COHb, MetHb, Pleth 
Variability Index
Measures heart rate, 
O2 saturations, and 
Hb
Clip-type finger probe 
only
Clip-type probe which 
can be used on fingers 
or toes, ear probe also 
available
Ring-shaped sensor 
which fits on a finger, 
a pneumatic cuff 
occludes blood supply 
transiently




No details regarding 
wavelengths
Signal processing 
close to the probe
Signal processing in 
the display unit
Signal processing in 
the display unit









No information on 
how compatible the 
display units is
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Novel Device Radical-7 NBM-200
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Table 2. Summary of participants’ characteristics. Values are number or 
median (IQR [range]). 
IQR=Interquartile Range 
BMI=Body Mass Index 
Number of subjects 100
Height; cm 164 (161-168 [150-178])
Weight; kg 71.9 (62.95-80.25 [49-114.9])
BMI; kg.m-2 25.9 (23.58-29.83 [19.8-39])
Haemoglobin; g.l-1 117 (110.8-124 [75-140])
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Figure 1. A Bland-Altman plot for the comparison between plasma 
haemoglobin (Hb) estimation using the novel device and the laboratory 
full blood count (FBC). The solid horizontal line indicates the mean 
difference (bias) between methods; the broken lines indicate the 95% 
limits of agreement. 
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Figure 2. A scatter plot for the comparison between plasma 
haemoglobin (Hb) estimation using the novel device and the laboratory 
full blood count.  
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Cardiac output monitoring using a pulmonary artery catheter can 
estimate stroke volume, but is invasive and can lead to complications. 
Lesser invasive devices exist but none are truly non-invasive. We 
evaluated the ability of a prototype device both to measure stroke 
volume and to identify fluid responsiveness in patients undergoing 
cardiac surgery. 
Methods 
Twenty patients undergoing elective cardiac surgery with pulmonary 
artery pressure monitoring were enrolled. Measurements of stroke 
volume and cardiac output were made using the pulmonary artery 
catheter and the novel device before and after the administration of a 
fluid bolus. The two methods of measurement were compared using 
scatter plots. Fluid responders were retrospectively identified, and a 
receiver operating characteristic curve was plotted to evaluate the ability 
of the novel device to predict fluid responsiveness.  
Results 
The cardiac output and stroke volume as measured by the novel device 
correlated poorly with the pulmonary artery catheter, with an r2 of 0.0145 
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and 0.0558 respectively. The area under the receiver operating 
characteristic curve for the prediction of fluid responsiveness by the 
novel device was 0.5844.  
Conclusions 
Our study shows that the novel device is not useful for the measurement 




There is no gold standard for the clinical measurement of cardiac output 
and stroke volume, although the bolus thermodilution technique via 
pulmonary artery catheters (PACs) has been accepted as a “practical” 
gold standard since the 1970s1. However, this technique is associated 
with complications2, 3 and has an inherent error of up to 20%1. The 
continuous thermodilution cardiac output (CCO) technique has been 
shown to agree clinically with the bolus thermodilution technique in 
several studies4, 5. Over the last number of years, various devices have 
been developed to allow measurement of cardiac output and stroke 
volume (PiCCO (Pulsion Ltd, Munich, Germany), LiDCO (LiDCO Ltd, 
London, England), Doppler oesophageal probes, partial CO2 re-
breathing, etc). Apart from bioimpedance methods such as NICOM 
(Cheetah Medical, Tel Aviv, Israel), none of these methods are truly non-
invasive. Despite a promising early study demonstrating usefulness6, 
NICOM (now marketed as “Starling SV”) has been shown to not be 
reliable for estimating cardiac output or for predicting fluid 
responsiveness7. 
A rapidly responding, automated and truly non-invasive measurement of 
cardiac output, stroke volume or fluid responsiveness would avoid the 
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complications of more invasive methods, and could allow for easier goal-
directed management of surgical patients.  
It is known that the arterial pulse pressure variation (PPV), a system based 
on analysing the arterial pressure waveform, can reflect cardiac output 
and predict fluid responsiveness8. Indeed, dynamic indices such as PPV 
stroke volume variation (SVV) are now recommended for the 
measurement of fluid responsiveness9. 
Studies have shown that the information derived from the pulse oximetry 
plethysmograph (pulse oximetry plethysmograph variation or POPV) is as 
good as PPV for predicting fluid responsiveness10 and is a reliable 
indicator of mild hypovolaemia in anaesthetised patients11. However, 
none of the POPV systems (which are no more invasive than a standard 
pulse oximetry probe) present automated data. However, there are no 
commercially available automated systems for calculating or monitoring 
POPV. In studies11, the PPG waveform was printed out and the variation 
measured and calculated manually. 
Masimo (Irvine, CA, USA) has developed a device, which measures the 
“pleth variability index” or PVI. PVI is a measure of the variation in the 
perfusion index (PI) which is calculated from the formula PI=(AC/DC) x 
100, where AC is the varying portion of the light absorbance signal 
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caused by pulsatile blood flow, and DC is the constant portion of the 
light absorbance signal caused by skin, muscle, tendon, bone, and 
venous (non-pulsatile) blood12. Changes in PVI have been shown to 
reflect changes in POPV12, and therefore have the potential to be used 
as a guide to fluid management of intraoperative patients13. 
The Optical Fibre Sensor Research Centre at the University of Limerick 
(UL) together with the Institute of General Electrical Engineering at the 
University of Rostock, Germany have co-developed a novel prototype 
research device that has the potential to non-invasively and automatically 
process the pulse oximetry plethysmograph to calculate indices based 
on stroke volume14, and this could be also be used to assess fluid 
responsiveness. The device is based on a novel mathematical analytical 
process, which can potentially provide a continuous and automatic 
indirect measure of stroke volume/cardiac output. It does not rely on PI 
or PVI, but instead analyses the beat-to-beat changes in the area under 
the curve of the plethysmograph to reflect variations in stroke volume15. 
As the device is entirely non-invasive, it avoids the specific complications 
associated with PACs and other methods of cardiac output 
measurement. There are potential cost-savings in that the use of more 
expensive cardiac output measurement devices could be avoided. The 
ease of use associated with such a non-invasive device would allow more 
flexible usage and if it could reliably predict responsiveness to fluid 
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administration it may result in clinical benefits associated with devices 
which have already been shown to predict fluid responsiveness16. 
Differences between this device and the NICOM device are summarised 
in Table 1. 
In this study, two hypotheses were tested: (i) that the output from this 
prototype device correlates with pulmonary artery catheter 
measurements of cardiac output or stroke volume via the continuous 
thermodilution technique; and (ii) that the this device can be used to 
predict those patients who would respond to a fluid bolus as indicated 




The study was registered with the Australian New Zealand Clinical Trials 
Registry with the reference number ACTRN12612000770864. Following 
local institutional (Research Office, Auckland City Hospital; registration 
number A+5549) and national (New Zealand Health and Disability Ethics 
Committee; registration number NTX/12/06/058/AM05) ethical 
committee approval and having obtained written informed consent from 
each, 20 adult patients scheduled to undergo elective cardiac surgery 
where the use of a pulmonary artery catheter for cardiac output 
monitoring was deemed necessary were recruited for this prospective 
study at Auckland City Hospital, Auckland, New Zealand between 
October 2013 and March 2016. The sample size of 20 patients was 
selected based on a power analysis in a previous study17 which found 
that 19 patients were needed to detect a difference of 0.3 in the areas 
under the receiver operating characteristic (ROC) curves between the 
standard method and the test method (alpha 0.05, beta 0.2), and other 
studies18, 19. 
 Exclusion criteria were patient refusal (or inability to provide informed 
consent), left ventricular ejection fraction less than 30%, cardiac rhythm 
other than sinus rhythm, known moderate (or worse) tricuspid or aortic 
regurgitation (which can lead to inaccuracies in thermodilution estimates 
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of CO or inconsistencies in the plethysmograph respectively), the use of 
an intra-aortic balloon pump or the known presence of 
haemoglobinopathy. 
Each patient’s age, gender, height, weight, and body mass index were 
recorded. Following instigation of routine monitoring, and insertion of an 
arterial line for invasive blood pressure monitoring, anaesthesia was 
induced. A central venous catheter was inserted in the right internal 
jugular vein and a pulmonary artery catheter was inserted and positioned 
appropriately. The novel device (ND) was placed on an appropriate 
finger. Once cardiac index (CI) had stabilised, baseline haemodynamic 
data (heart rate (HR), mean arterial pressure (MAP), central venous 
pressure (CVP) and CI), and the reading from the novel device were 
recorded three times at one minute intervals. CI was recorded using a 
Vigilance II Patient Monitor (Edwards Lifesciences, Irvine, CA, USA). 
Investigators were blinded to the output from the novel device until the 
data was extracted from the device following completion of the entire 
study. 
A crystalloid fluid bolus (Plasma-Lyte 148, Baxter International Inc., 
Deerfield, IL, USA) of 7 ml.kg-1 at 1 ml.kg-1.min-1 (based on previous 
studies19) was administered. A repeat set of haemodynamic readings was 
taken two minutes following completion of the fluid bolus, three times at 
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one minute intervals. No other fluids or vasopressors were administered 
during this period, and no changes were made to the ventilatory 
settings. For each reading, before and after the fluid bolus, cardiac 
output (CO) and stroke volume (SV) were calculated for each 
corresponding CI. Readings of CI taken from the PAC using the 
continuous thermodilution technique were considered the reference 
technique. Patients were considered ‘responders’ to the fluid bolus if 
their calculated SV increased by 10% or more (as per Hood et al20). 
Precision of the reference technique (for CO) was calculated using the 
three consecutive readings taken each time. An inter-patient coefficient 
of variation (2SD/mean) lower than 30% was considered an acceptable 
limit a priori21, 22. Scatter plots were constructed using mean values of 
three readings both before and after the fluid bolus for the comparisons 
of CI vs. ND and SV vs. ND. Lines of equality were plotted and Pearson’s 
correlation coefficient was calculated in each case. A receiver operating 
characteristic (ROC) curve was constructed for the ability (or otherwise) of 
the novel device to predict fluid responsiveness, and the area the ROC 
curve (AUROC) was calculated. All data were recorded on case record 
forms and subsequently inputted into both Excel (Microsoft, Redmond, 
WA, USA) for analysis and graphs were prepared using Stata: Version 
13.1 (StataCorp LP, College Station, TX, USA). 
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5.4.Results 
In total, 25 patients were approached for possible participation in the 
study. Two patients declined to take part. One patient developed atrial 
fibrillation immediately following induction of anaesthesia and so was 
excluded from the study without taking any readings or giving the fluid 
bolus. A further patient was excluded following completion of our 
readings as they were unexpectedly found to have severe tricuspid 
regurgitation on intraoperative transoesophageal echocardiography. A 
final patient was excluded prior to any readings or fluid bolus 
administration as the novel device failed to function. Baseline 
characteristics of the 20 completed study cases are summarised in Table 
2. During analysis of the data recorded by the novel device, it was found 
that data belonging to two patients were missing and so only 18 
patients’ completed readings were used for production of our graphs 
and comparative analysis. Of these patients, 7 (39%) were identified as 
responders to the fluid bolus. 
Precision of the reference technique is shown in Table 3 and is within the 
acceptable a priori limit. Precision of the novel device is included for 
comparison. Scatter plots with regression lines comparing the correlation 
between the novel device (including data from before and following the 
fluid bolus) and both CO and SV are shown in Figure 1 with the 
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corresponding value of linear regression coefficient (r2). The ROC curve 
along with the area under the ROC curve for the ability of the novel 
device to predict the responsiveness to fluid is shown in Figure 2. 
Cohen’s kappa was 0.16 which indicates slight agreement between the 
methods in predicting fluid responsiveness23. 
Although recommended by Critchley et al24, polar plots were not 
produced as to do so requires that both methods utilise the same units 
of measurement, which is not the case in this study. For the same reason 
it was not possible to use Perrino et al’s25 four-quadrant plots. 
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5.5.Discussion 
The results of this study show that the novel device correlated poorly 
with both CO and SV measured from the reference technique, with an r2 
of 0.0145 and 0.0558 respectively (Figure 1). In addition, the area under 
the ROC curve (AUROC) was 0.5844 which confirms that the novel 
device is not useful in the prediction of responsiveness to a fluid bolus of 
this type and size in this population. The AUROC improves to 0.614 
when the log of the output from the novel device is used for analysis (not 
shown). Consequently, both hypotheses can be rejected. 
To the authors’ best knowledge, this is the first study using this particular 
method of non-invasively identifying fluid responsiveness and therefore 
no previously published work exists to allow comparison in this regard. 
Also, there are no major publications featuring investigations into 
automated methods of calculating POPV. The initial studies of this device 
were proof-of-concept studies14, 15. The authors did not specify the 
number of patients studied, other than stating that some were intensive 
care patients (which comprised ‘stable’ and ‘unstable’ patients) and 
others were patients undergoing dialysis. The data from these patients 
was not summarised or analysed in any meaningful way, and indeed one 
graph used in each paper appeared to be the same. As such, it is difficult 
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to draw conclusions from these papers as to how accurate or reliable the 
device might be. 
However, other studies investigating plethysmographic waveform 
analysis have shown some promise. Chu et al26 produced a systematic 
review into the use of Masimo’s Pleth Variability Index (PVI) for the 
prediction of fluid responsiveness in ventilated patients in 2016. They 
found a pooled AUROC of 0.88 for the 18 trials included, which would 
indicate that PVI is useful for the prediction of fluid responsiveness in 
these patients. A further and more recent systematic review of 25 studies 
confirmed this result27. Both these reviews found no heterogeneity 
between the included studies. In a large review published in 2018, 
Messina et al28 stated that the reliability of both PPV and SVV in 
predicting fluid responsiveness was limited with a high degree of 
heterogeneity.  
Of note, Cannesson et al29 described a ‘gray zone’ in which fluid 
responsiveness cannot be predicted in 25% of patients during GA and 
that this ‘gray zone’ needs to be defined for each dynamic index used to 
predict fluid responsiveness. This does not yet appear to have been 
accounted for in major studies of such indices.  
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Our study was limited by its small size. Although precision of the 
reference technique is within the a priori limits of 30%, the precision of 
the novel device is poor and this would undoubtedly have led to the 
poor performance of the device overall. The reasons for the poor 
precision are not clear, but it could be due to the fact that the device was 
not covered to protect it from interference from ambient lighting in the 
theatre, or due to electromagnetic interference from other sources within 
the operating theatre environment. One of the steps taken by the 
developers to prevent interference was to place a signal processor along 
the lead closer to the light receptor and point of origin of the signal, 
although the effectiveness of this has not been measured to date. 
Notwithstanding the small sample size, the overall response to the fluid 
bolus was low (39%) and was negative in many cases. Other studies 
assessing fluid responsiveness have documented responses of 
approximately 50%29. This smaller number of responders makes it less 
likely that any device would detect fluid responsiveness. A further 
problem is that there does not appear to be a clear definition of what 
constitutes a positive response to a fluid bolus. Messina’s review article28 
clearly demonstrates this problem with the included studies defining a 
response as increases in SV of greater than or equal to 5%, 10%, 12%, 
15%, 20%, and 25%. Other studies have relied upon changes in CI30, 31, 
CO29, or MAP (via changes in CO)32. According the Squara et al22, 
numbers displayed by pulmonary artery catheter continuous cardiac 
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output (PAC CCO) devices represent the average of at least the five 
previous readings, each taken as a 1-minute running average. This 
diminishes the time response of the device to actual change in CO and it 
may be that the reference technique in our study did not physically have 
enough time to detect responders to the fluid bolus. Despite this, Squara 
notes that the PAC CCO remains the most commonly used reference 
technique in fluid responsiveness studies. Finally, the ROC curve 
approach does not take into account the existence of an overlap 
between responders and non-responders33, something analogous to 
Cannesson’s ‘gray zone’ discussed earlier29. 
While ongoing research continues to indicate that PVI may be a useful 
tool for the prediction of fluid responsiveness, the novel device requires 
technical refinement before it could be considered for further study. 
The results of this investigation indicate that the novel device is currently 
not suitable for use in the measurement of stroke volume or as a tool to 
predict fluid responsiveness. 
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Measurements derived from 
photoplethysmography
Measurements derived from 
bioimpedence
Single finger clip sensor placed 
over a single digit
Four pads placed on the thorax, 
each containing an electrode 
(emitter) and a sensor
Published algorithm Proprietary algorithm
Prototype phase FDA-approved
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Table 2. Summary of patients' characteristics and type of surgery. Values 
are number, median (IQR [range]) or number (proportion). 
Number of subjects 20
Age; years 64.5 (61.5-72.25 [39-80])
Gender; M: F 13 : 7
Height; cm 166 (162.75-172.25 [155-187])
Weight; kg 76 (72.13-81.40 [61-108])
Body Mass Index; kg.m-2 1.88 (1.81-1.95 [1.63-2.23])
Coronary Artery Bypass Graft 14 (70%)
Coronary Artery Bypass Graft & 
Mitral Valve Repair
2 (10%)
Mitral Valve Repair 1 (5%)
Mitral Valve Replacement 1 (5%)
Aortic Valve Replacement 1 (5%)




Table 3. Coefficients of Variation for reference technique measurements 
of cardiac output and stroke volume, and the Novel device. 
Cardiac Output Stroke Volume Novel Device
Pre-bolus; % 15.06 15.87 64.76
Post-bolus; % 9.65 13.55 46.76
Mean; % 12.36 14.71 55.76
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5.7.Figures 
Figure 1 (following page). Scatter plots for the comparisons between the 
novel device, and (a) cardiac output and (b) stroke volume. The shaded 
areas represent the 95% confidence intervals around the lines of 
regression. r2 is displayed accordingly. 
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Figure 2. Receiver operating characteristic (ROC) curve for the ability of 
the novel device to predict fluid responsiveness as detected by a 10% (or 
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6.Conclusions 
6.1.Clinical implications and future directions – studies 
1 and 2 
Study 1 – Clinical evaluation of a novel technology for the non-invasive 
and continuous measurement of plasma haemoglobin concentration. 
Study 2 – Clinical evaluation of a novel device for the non-invasive and 
continuous measurement of haemoglobin in the obstetric population. 
The principal findings from these studies show that this novel device, in 
its current form, is not a suitable method of measurement of 
haemoglobin compared to the commonly used reference methods 
(laboratory full blood count) in either patients undergoing cardiac surgery 
or pregnant patients.  
The studies have some strengths: the assessment of repeated measures 
in the same patients (study 1, analysed as per Bland and Altman1), and 
the large number of patients assessed for inter-patient variability (study 
2). However, the limitations were the small number of patients included 
in study 1, and the narrow range of haemoglobin values (IQR 110.8-124 
g.l-1) in study 2. 
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The United States Food and Drug Administration (FDA) defines process 
validation as “establishing by objective evidence that a process 
consistently produces a result or product meeting its predetermined 
specifications”2. The clinical result of the novel device must be the 
accurate and reliable identification of patients in need of a blood 
transfusion. As this device does not consistently produce the intended 
results, it is appropriate to conclude that this device would fail process 
validation and therefore would not be suitable for clinical use. 
Masimo Corporation (Irvine, California, USA) have developed a similar 
technology, now incorporated into several devices, which non-invasively 
and continuously measures haemoglobin. There are now many published 
studies confirming the accuracy and reliability of this technology. Most 
recently, this technology was shown to more accurately estimate the 
timing for invasive haemoglobin measurements than clinicians3, and also 
to result in cost savings by significantly reducing the need for blood 
transfusion4. As most of the information regarding the functioning of 
Masimo’s device is unknown, one can only assume that the reasons 
behind its improved performance compared with the novel device of this 
thesis is that it uses wavelengths of light more suited to the 
measurement of haemoglobin, that the algorithms used allow for a more 
accurate analysis of the waveforms and measurement of haemoglobin, 
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and that their correlation curves were calculated using data from large 
sample sizes across many physiological situations. 
Wearable electronic monitoring devices are becoming cheaper and more 
common. Several wearable medical-grade devices, such as the FreeStyle 
Libre Flash system (Abbott Diabetes Care, Alameda, California, USA)5, 
which allow continuous glucose monitoring have already received FDA 
approval. While the market is saturated with non-FDA approved heart 
rate monitors, some have received FDA approval, and one has received 
approval for the detection of atrial fibrillation6. It is likely simply a matter 
of time before a wearable device will receive approval for the 
measurement of haemoglobin. 
In order to establish process validity, the novel device will require several 
refinements. These may include improvements to the processing 
algorithm, or to the hardware and software signal processing. Further 
studies with volunteers confirming an improved performance will then be 
needed before larger-scale clinical trials could hopefully establish 
process validity. However, given its poor performance to date, and the 
establishment of clinically acceptable alternative devices with the 
promise of further developments with miniaturised and cheaper devices, 
the novel device is not likely to have any future clinical role. 
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6.2.Clinical implications and future directions – study 3 
Study 3 – Evaluation of a novel, non-invasive method for the estimation 
of stroke volume and the prediction of fluid responsiveness. 
The principals findings of this study showed that this form of 
plethysmographic waveform variation analysis does not correlate well 
with either cardiac output or stroke volume and is not useful for the 
prediction of those patient who would respond appropriately to a fluid 
bolus. 
Despite the findings, the study had numerous strengths. The study 
investigated not just simple correlation between the methods of 
measurement, but also the trend of the readings or the “degree of 
correct identification of response to (an) intervention” as recommend by 
Chikhani and Moppett in their 2011 editorial in the British Journal of 
Anaesthesia7. The novel device was compared with the commonly 
accepted “gold standard” of cardiac output monitoring using a 
pulmonary artery catheter and the thermodilution method and the 
precision of the gold standard was confirmed. The twenty participants 
recruited should have been enough to demonstrate at least some 
degree of correlation between the methods of measurement. 
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However, due to the unusually small number of fluid responders 
identified, twenty participants was probably not enough, in retrospect, to 
detect a sizeable number of responders. In addition, Squara identified a 
number of limitations in relation to continuous cardiac output monitoring 
using a pulmonary artery catheter (such as a poor time response) which 
might mean that true responders were not detected in the first place8. 
Some commentators have stated that precise measurements of cardiac 
output or stroke volume are not necessary or even helpful and that the 
focus of research should solely be on developing devices which can 
identify fluid responders7, 9. This could be assisted by using a different 
reference method where measurements of stroke volume are truly real-
time (for example transoesophageal echocardiography, or a continuous 
cardiac output measurement device with better averaging8). This would 
be a goal worth pursuing, as such a validated, easy-to-use, and truly non-
invasive trend monitor would hopefully lead to better outcomes in terms 
of decreased patient perioperative morbidity and/or mortality with 
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7.Publications arising 
A portion of Chapter 1 (Introduction) was published as an editorial in the 
journal Anaesthesia under the title “Point-of-care haemoglobin 
measurement - state of the art or a bleeding nuisance?”1 
Chapter 2 (Study 1) was published as an original research article in the 
journal Anaesthesia with the title of “Clinical evaluation of a novel 
technology for non-invasive and continuous measurement of plasma 
haemoglobin concentration.”2 
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Title of Proposed Work:  
A novel, non-invasive, optical, device for the measurement of total 
haemoglobin and monitoring of stroke volume/fluid responsiveness – 
initial clinical evaluation. 
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Cork University Hospital, Cork, Ireland. 
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Supervisors: 
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Overall Objective: 
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To assess the accuracy and usability of a novel, non-invasive, optical 
device with regard to: 
The device’s measurement of total haemoglobin; 
The device’s measurement of indices reflecting stroke volume and trends 
in stroke volume variation following fluid challenges. 
To achieve this, I propose to carry out three clinical studies. 
(1). A prospective observational study examining the correlation 
between estimates of total haemoglobin concentration using i. the 
novel device and ii. a laboratory ‘gold standard’ (XE-2100, Sysmex 
Corp., Kobe, Japan) in patients undergoing cardiac surgery (a clinical 
setting associated with significant blood loss and haemodynamic 
fluctuations). 
(2). A prospective observational study examining correlation between 
estimates of total haemoglobin concentration using i. the novel device 
and ii. a laboratory ‘gold standard’ (XE-2100, Sysmex Corp., Kobe, 
Japan) in patients presenting for their 20-week antenatal check-up (an 
elective outpatient clinical setting). 
(3). A prospective observational study examining correlation between 
estimates of cardiac output using i. a modified version of the novel 
device and ii. a clinical ‘gold standard’ pulmonary artery catheter-
based technique. 
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Background and Significance 
Haemoglobin 
In many clinical situations, haemoglobin concentrations need to be 
determined frequently and/or urgently (such as during cardiac or vascular 
surgery, in trauma patients or in the intensive care setting). This usually 
requires sampling and processing of blood either in the laboratory 
(formal Full Blood Count (FBC)), or with a point-of-care analyser (such as 
the GEM Premier 4000). A continuous, non-invasive and accurate 
method would allow for more rapid decision-making in these situations.  
The Optical Fibre Sensor Research Centre at the University of Limerick 
(UL) together with the Institute of General Electrical Engineering at the 
University of Rostock, Germany have co-developed a device for the non-
invasive, optical, real-time measurement of haemoglobin, which 
functions similar to a standard pulse-oximeter 1, 2. A similar commercial 
device is available (Rainbow SET Pulse CO-Oximeter, Masimo 
Corporation, Irvine, CA, USA) which has been tested clinically with mixed 
results. Masimo’s device is different in that it uses seven wavelengths of 
light, while the novel device uses just two wavelengths of light, which has 
a potential cost saving. Additionally, the device has been shown to 
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accurately measure very low haemoglobin concentrations in-vitro (38.7 
g.l-1)3. However, this device has yet to be tested clinically. 
Haemodynamic monitoring 
There is no gold standard for the clinical measurement of cardiac output, 
although the bolus thermodilution method has been accepted as a 
“practical” gold standard since the 1970s4. However, this method is 
associated with complications5, 6. Over the last number of years, various 
devices have been developed to allow measurement of cardiac output 
(PiCCO, LiDCO, Doppler oesophageal probes, partial CO2 re-breathing, 
etc). Apart from bioimpedance methods (such as NICOM7), none of 
these methods are truly non-invasive. 
A rapidly responding, automated and truly non-invasive measurement of 
fluid responsiveness would avoid the complications of more invasive 
methods, and could allow for easier goal-directed management of 
surgical patients.  
It is known that the arterial pulse pressure variation (PPV), a system based 
on analysing the arterial pressure waveform, can reflect cardiac output 
and predict fluid responsiveness8. 
156
Studies have shown that the information derived from the pulse oximetry 
plethysmograph (the pulse oximetry plethysmograph variation or POPV) 
is as good as PPV for predicting fluid responsiveness9 and is a reliable 
indicator of mild hypovolaemia in anaesthetised patients10. 
However, none of the POPV systems (which are no more invasive than a 
standard pulse oximetry probe) present automated data. Masimo have 
various devices, which measure pleth variability index (PVI). This 
calculates the variation in the perfusion index (PI) which is calculated 
from the formula PI=(AC/DC) x 100 (where AC is the varying portion of 
the light absorbance signal caused by pulsatile blood flow, and DC is the 
constant portion of the light absorbance signal caused by skin, muscle, 
tendon, bone, and venous (non-pulsatile) blood)11. Changes in PVI have 
been shown to reflect changes in POPV11, and therefore has the 
potential to be used as a guide to fluid management of intraoperative 
patients12. 
The novel device non-invasively and automatically processes the pulse 
oximetry plethysmograph to calculate indices based on cardiac output/
fluid responsiveness3. The device is based on a novel mathematical 
analytical process, which potentially can provide a continuous and 
automatic indirect measure of cardiac output. It does not rely on PI or 
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PVI, but instead analyses the beat-to-beat changes in area-under-the-
curve of the plethysmograph to calculate an index of stroke volume13. 
Device advantages 
This device has the potential to offer many advantages over other similar 
devices, as presented in table 1 below. The device would be entirely 
non-invasive and therefore without the specific complications associated 
with both laboratory FBCs and other methods of cardiac output 
measurement. There are potential cost-savings in that fewer FBC tests 
could be ordered, or the use of more expensive cardiac output 
measurement devices could be avoided. The device itself utilises fewer 
wavelengths of light than Masimo’s device, which has a potential cost-
saving. The ease of use associated with such a non-invasive device would 
allow more flexible usage and if it could reliably predict responsiveness 
to fluid administration it may result in clinical benefits associated with 
systems which have already be shown to predict fluid responsiveness14. 
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Study 1: Clinical validation of a novel device for the non-invasive 
continuous measurement of haemoglobin. 
Co-investigators: 
F. Desmond*, G. Lean†, U. Timm†, E. Lewis†, G. Shorten* 
*Cork University Hospital, Cork, Ireland 
†Optical Fibre Research Centre, University of Limerick, Limerick, Ireland 
Background and Significance 
During cardiac surgery patients undergo large and rapid changes in total 
haemoglobin concentration secondary to blood loss, dilution (pump 
prime), or blood product transfusion at various points. Additionally, the 
institution of cardiopulmonary bypass (CPB) causes gross haemodilution, 
which is partially corrected following discontinuation of CPB. These cases 
present ideal opportunities to study fluctuations in haemoglobin within 
the same patient. 
I propose to compare total haemoglobin concentration estimation using 
the novel device with i. the GEM Premier 4000 point-of-care analyser and 
ii. a standard laboratory device, in patients undergoing cardiac surgery. 
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Hypothesis 
That a non-invasive, continuous pulse-haemoglobinometer can 
accurately and reliably measure haemoglobin concentration in patients 
undergoing cardiac surgery (with cardiopulmonary bypass). 
Methods 
The setting will be patients undergoing elective cardiac surgery involving 
cardiopulmonary bypass at Cork University Hospital. Following local 
ethical approval and with the informed written consent of each, 25 
patients will be admitted to the study. Each will have the following 




• Haemoglobin (a recent laboratory FBC) 
• Temperature 
• Smoking history (active/previous/non-smoking, pack years, date of 
cessation) 
• Surgery to be carried out 
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Following induction of anaesthesia, the novel device will be fitted on the 
index finger of each patient’s right hand (unless the right radial artery is 
to be used for grafting in which case the left index finger will be used). 
At four time points, an arterial blood sample will be taken and processed 
on the GEM Premier 4000 point-of-care analyser with a sample also 
being sent to the laboratory for FBC measurement. At these time points, 
the patient’s total haemoglobin as displayed by the study device will also 
be noted. 
Arterial samples will be taken as follows (using aseptic technique): 
• 10cc of blood/hep-saline flush is drawn via the most distal port (i.e. 
that closest to the patient) 
• 6cc of blood is then drawn and 4.1cc is transferred to a standard Li-
Heparin blood sample bottle (for the laboratory FBC) 
• The remaining blood is transferred into an arterial blood gas 
syringe which is then processed using the GEM Premier 4000 
• Having ensured no air bubbles are present in the system, the 
arterial line is flushed using the arterial line flushing mechanism until 
clear of blood 
• The original 10cc of blood/hep-saline is returned to the patient via 
a peripheral line 
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The time points shall be: 
• At skin incision (start of surgery) 
• Two minutes following completion of first dose of heparin (pre-CPB) 
• Two minutes following completion of administration of the first 
dose of protamine (post-CPB) 
• At completion of final skin suture (end of surgery) 
The laboratory FBC will be considered the gold standard. A bivariate 
plot will be constructed and Pearson’s Correlation Coefficient, r will be 
calculated for the following comparisons; 
• Novel device vs. laboratory FBC (primary outcome) 
• Novel device vs. GEM Premier 4000 
• GEM Premier 4000 vs. laboratory FBC 
Each will be tested for significance (p<0.05) and tested for agreement 
using the Bland-Altman method19 as appropriate. 
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Study 2: Clinical validation of a novel device for the non-invasive 
measurement of haemoglobin in the obstetric population. 
Co-investigators: 
S. F. Sultan*, G. Lean†, U. Timm†, E. Lewis†, M. Harnett*, G. Shorten* 
*Cork University Hospital, Cork, Ireland 
†Optical Fibre Research Centre, University of Limerick, Limerick, Ireland 
Background and Significance 
The World Health Organization has reported that 18% of pregnant 
women from industrialized countries have iron-deficiency anaemia20. 
Pregnant patients attending antenatal clinics frequently undergo blood 
sampling for haemoglobin measurement. This is an invasive procedure 
involving venepuncture (painful) with the possibility of infection, and the 
results are not usually available until some time later. At present, all 
pregnant women booked into Cork University Maternity Hospital have a 
FBC taken at the 20-week antenatal check. Most of these women would 
also have FBCs sent by their general practitioner prior to booking, and 
all those considered to be at risk will have more frequent blood 
sampling. A non-invasive, point-of-care device would allow for 
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unrestricted, painless and risk-free rapid haemoglobin assessment, while 
decreasing the cost of processing blood samples. Earlier and more 
frequent sampling may also allow for more timely iron supplementation 
in those found requiring such treatment. 
Hypothesis 
That a non-invasive, continuous pulse-haemoglobinometer can 
accurately and reliably estimate haemoglobin concentration in patients 
attending an out-patient antenatal clinic for the 20-week check-up. 
Methods 
The setting will be obstetric patients presenting electively for their 20-
week check-up at the outpatient antenatal clinics, who are routinely 
having a blood sample drawn for a FBC. Following local ethical approval 
and with the informed written consent of each, 100 such patients will be 






• Smoking history (active/previous/non-smoking, pack years, date of 
cessation) 
The novel device will be placed on the index finger of the opposite 
upper limb to that being used for blood sampling. This is to avoid any 
concerns about the tourniquet interfering with light absorption in the 
device. Whichever hand is used will be briefly covered in a light proof 
material similar to a glove in order to minimise interference from ambient 
light. The device will be left in place for one minute in order for it to 
stabilise its reading. As the blood sample is drawn, the haemoglobin as 
measured by the device will be noted. 
The laboratory FBC will be considered the gold standard. A bivariate 
plot will be constructed and Pearson’s Correlation Coefficient, r will be 
calculated for the novel device against the laboratory FBC. This will be 
tested for significance (p<0.05) and further testing using the Bland-
Altman method19, and/or calculation of bias and precision will be carried 
out as appropriate. 
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Study 3: A novel, non-invasive device for the detection of a response to a 
fluid challenge - comparison with bolus thermodilution in elective 
coronary artery bypass grafting patients. 
Co-investigators: 
G. Lean†, U. Timm†, E. Lewis†, D. Breen*, S. Allen‡ 
†Optical Fibre Research Centre, University of Limerick, Limerick, Ireland 
*Cork University Hospital, Cork, Ireland 
‡Auckland City Hospital, Auckland, New Zealand 
Hypotheses 
(1)That a novel, automated, non-invasive device analysing the pulse 
oximetry plethysmographic waveform can correlate with cardiac 
output (as measured using the bolus thermodilution method) in 
anaesthetised, ventilated and haemodynamically stable patients about 
to undergo coronary artery bypass grafting 
(2)That this novel, automated, non-invasive device can detect a 
positive response (measured as an increase in a marker of stroke 
volume/cardiac output), or lack thereof, to a fluid bolus in 
anaesthetised, ventilated and haemodynamically stable patients about 
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to undergo coronary artery bypass grafting (as detected using the 
bolus thermodilution method). 
Methods 
This will be a prospective study involving 20 patients scheduled for 
coronary artery bypass grafting at Auckland City Hospital, Auckland, New 
Zealand, who would ordinarily have a pulmonary artery catheter (PAC) 
inserted. Full informed consent will be obtained from each participant. 
Following attachment of routine monitors, and insertion of an arterial line 
for invasive blood pressure monitoring, anaesthesia will be induced and 
a pulmonary artery catheter will be inserted. The novel device will be 
placed on an appropriate finger. After a period of 15 minutes without 
adjustment in vasopressor/inotrope infusion rates, ventilation settings, or 
fluid delivery, a baseline reading for cardiac output (CO) will be taken 
from the PAC in accordance with the manufacturers guidelines. At the 
same time, the reading from the novel device will be recorded. A fluid 
bolus of colloid (7mL/kg at 1mL/kg/min) will be given, and a second set 
of haemodynamic readings will be taken. 
The values for cardiac output will be compared using the Bland-Altman 
method19. Bias, precision and correlation will also be assessed. Polar 
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8.2.Protocol for Study I 
DETAILED PROTOCOL FOR: 
Clinical validation of a novel device for the non-invasive continuous 
measurement of haemoglobin. 
A. Broderick*, U. Timm†, G. Leen†, E. Lewis†, G. Shorten* 
*Department of Anaesthesia and Intensive Care, Cork University Hospital, 
†Optical Fibre Sensor Research Centre, University of Limerick 
Introduction 
In many clinical situations, haemoglobin concentrations need to be 
determined frequently and /or urgently (such as during cardiac or 
vascular surgery, in trauma patients or in the intensive care setting). This 
usually requires sampling and processing of blood either in the 
laboratory (formal Full Blood Count (FBC)), or with a point-of-care 
analyser (such as the GEM Premier 4000). A continuous, non-invasive and 
accurate method would allow for more rapid decision-making in these 
situations.  
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The Optical Fibre Sensor Research Centre at the University of Limerick 
together with the Institute of General Electrical Engineering at the 
University of Rostock, Germany have co-developed a device for the non-
invasive, optical, real-time measurement of haemoglobin, which 
functions similar to a standard pulse-oximeter1, 2. Such devices have 
been developed before, such as the Rainbow SET Pulse CO-Oximeter 
(Masimo Corporation, Irvine, CA, USA), but no clinical validation studies 
of such devices have been published fully in peer-reviewed scientific 
journals.  
Patients undergoing cardiac surgery undergo large and rapid changes in 
total haemoglobin concentration secondary to blood loss, dilution (pump 
prime), or blood product transfusion at various points. Additionally, the 
institution of cardiopulmonary bypass (CPB) causes gross haemodilution, 
which is partially corrected following discontinuation of CPB. These cases 
present ideal opportunities to study fluctuations in haemoglobin within 
the same patient. 
Objectives 
To compare total haemoglobin concentration estimation using the novel 
device with i. the GEM Premier 4000 point-of-care analyser and ii. a 
standard laboratory device, in patients undergoing cardiac surgery. 
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Outcomes 
Total haemoglobin as measured at four time points by the study device, 
the GEM Premier 4000 and the haematology laboratory. 
Study Design 
A prospective correlation study. 
Sample Size 
An arbitrary sample size of 25 patients will be used, with 4 samples taken 
from each patient (therefore resulting in 100 data points). 
Inclusion Criteria 
• Age >18 
• Patients undergoing any cardiac surgery which will involve 
cardiopulmonary bypass 
Exclusion Criteria 
• Patient refusal or inability to provide consent 
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• Any haemoglobinopathy (e.g. methaemoglobinaemia, sickle cell 
disease, thalassaemia) 
• Recent dye/contrast studies 
Methods 
Baseline data 
Following local ethical approval and with the informed written consent of 





• Haemoglobin (laboratory FBC from within the previous 24 hours) 
• Temperature 
• Smoking history (active/previous/non-smoking, pack years, date of 
cessation) 
• Surgery to be carried out 
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Setting 
The cardiothoracic operating theatres (numbers 1 and 1A) at Cork 
University Hospital. All blood samples will be collected in theatre. 
Following induction of anaesthesia, the novel device will be fitted on the 
index finger of the each patient’s right hand (unless the right radial artery 
is to be used for grafting in which case the left index finger will be used). 
Blood drawn for the study shall be analysed using the GEM Premier 4000 
point-of-care device located in theatre 1A only (i.e. the same device each 
time) and also sent to the haematology laboratory for standard FBC 
measurement. 
Intervention 
At four time points, an arterial blood sample will be taken and processed 
on the GEM Premier 4000 point-of-care analyser with a sample also 
being sent to the laboratory for FBC measurement. At these time points, 
the patient’s total haemoglobin as displayed by the study device will also 
be noted. In addition, at the first time point a blood sample will also be 
taken from the patient’s central line for measurement via the GEM 
Premier 4000 and sent to the laboratory for FBC measurement.  
Arterial samples will be taken as follows (using aseptic technique); 
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• 10cc of blood/hep-saline flush is drawn via the most distal port (i.e. 
that closest to the patient) 
• 6cc of blood is then drawn and 4.1cc is transferred to a standard Li-
Heparin blood sample bottle (for the laboratory FBC) 
• the remaining blood is transferred into an arterial blood gas syringe 
which is then processed using the GEM Premier 4000 
• having ensured no air bubbles are present in the system, the arterial 
line is flushed using the arterial line flushing mechanism until clear 
of blood 
• the original 10cc of blood/hep-saline is returned to the patient via a 
peripheral line 
The time points shall be: 
• At skin incision (start of surgery) 
• Two minutes following completion of first dose of heparin (pre-CPB) 
• Two minutes following completion of administration of the first 
dose of protamine (post-CPB) 
• At completion of final skin suture (end of surgery) 
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Assays 
• The novel device 
• GEM Premier 4000 (Instrumentation Laboratory, Bedford, MA, USA) 
• Laboratory FBC device 
Data management 
The laboratory FBC will be considered the gold standard. A bivariate 
plot will be constructed and Pearson’s Correlation Coefficient, r will be 
calculated for the following comparisons; 
• Novel device vs. laboratory FBC (primary outcome) 
• Novel device vs. GEM Premier 4000 
• GEM Premier 4000 vs. laboratory FBC 
Each will be tested for significance (p<0.05) and tested for agreement 
using the Bland-Altman method3. 
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8.3.Protocol for Study II 
DETAILED PROTOCOL FOR: 
Clinical validation of a novel device for the non-invasive measurement of 
haemoglobin in the obstetric population. 
A. Broderick*, U. Timm†, G. Leen†, E. Lewis†, M. Harnett*, G. Shorten* 
*Department of Anaesthesia and Intensive Care, Cork University Hospital, 
†Optical Fibre Sensor Research Centre, University of Limerick 
Introduction 
In many clinical situations, haemoglobin concentrations need to be 
determined frequently and/or urgently (such as during cardiac or vascular 
surgery, in trauma patients or in out-patient situations such as ante-natal 
clinics). This usually requires sampling and processing of blood either in 
the laboratory (formal Full Blood Count (FBC)), or with a point-of-care 
analyser. A continuous, non-invasive and accurate method would allow 
for more rapid decision-making in these situations.  
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The Optical Fibre Sensor Research Centre at the University of Limerick 
(UL) together with the Institute of General Electrical Engineering at the 
University of Rostock, Germany have co-developed a novel device for 
the non-invasive, optical, real-time measurement of haemoglobin, which 
functions similar to a standard pulse-oximeter1, 2.  
A similar commercial device is available (Rainbow SET Pulse CO-
Oximeter, Masimo Corporation, Irvine, CA, USA) which has been tested 
clinically with mixed results, however there have been no published data 
on out-patients (obstetric or otherwise). Masimo’s device uses seven 
wavelengths of light, while the novel device uses just two wavelengths of 
infrared light, which has a potential cost saving. Also, the novel device 
has been shown to accurately measure very low haemoglobin 
concentrations in-vitro (38.7 g.l-1)3. However, this device has yet to be 
tested clinically. 
The World Health Organization has reported that 18% of pregnant 
women from industrialized countries have iron-deficiency anaemia4. 
Pregnant patients attending antenatal clinics frequently undergo blood 
sampling for haemoglobin measurement. This is an invasive procedure 
involving venepuncture (painful) with the possibility of infection, and the 
results are not usually available until some time later. At present, all 
pregnant women booked into Cork University Maternity Hospital have a 
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Full Blood Count (FBC) taken at the 20-week antenatal check. Most of 
these women would also have FBCs sent by their general practitioner 
prior to booking, and all those considered to be at risk will have more 
frequent blood sampling. A non-invasive, point-of-care device would 
allow for unrestricted, painless and risk-free rapid haemoglobin 
assessment, while decreasing the cost of processing blood samples. 
Earlier and more frequent sampling may also allow for more timely iron 
supplementation in those found requiring such treatment. 
Objectives 
To compare total haemoglobin concentration estimation using the novel 
device with a standard laboratory device (XE-2100 Sysmex Corp., Kobe, 
Japan), in patients presenting for the 20-week antenatal check-up. 
Hypothesis 
A non-invasive, continuous pulse-haemoglobinometer can accurately 
and reliably estimate haemoglobin concentration in patients attending 
an out-patient antenatal clinic for the 20-week check-up. 
Outcomes 
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Total haemoglobin as measured non-invasively by the study device, and 
invasively by the haematology laboratory in patients having routine 
blood sampling at 20 weeks’ gestation. 
Study Design 
A prospective correlation study. 
Sample Size 
An arbitrary sample size of 100 patients will be used, resulting in 100 
data points for analysis. 
Inclusion Criteria 
• Age 18 
• Voluntarily presenting to the ante-natal clinic at CUMH for the 20 
weeks’ gestation check-up 
Exclusion Criteria 
• Patient refusal or inability to provide consent 
• Any haemoglobinopathy (e.g. methaemoglobinaemia, sickle cell 
disease, thalassaemia) 
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• Acrylic nail polish/coverings (interferes with light absorption by 
device) 
• Recent dye/contrast studies 
Methods 
Baseline data 
Following local ethical approval and with the informed written consent of 






• Smoking history (active/previous/non-smoking, pack years, date of 
cessation) 
Setting 
The antenatal clinics at Cork University Maternity Hospital.  
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Intervention 
The novel device will be placed on the index finger of the opposite 
upper limb to that being used for blood sampling. This is to avoid any 
concerns about the tourniquet interfering with light absorption in the 
device. Whichever hand is used will be briefly covered in a light proof 
material similar to a glove in order to minimise interference from ambient 
light. The device will be left in place for one minute in order for it to 
stabilise its reading. As the blood sample is drawn, the haemoglobin as 
measured by the device will be noted. 
Assays 
• The novel device 
• Laboratory FBC device (XE-2100) 
Data Management 
The laboratory FBC will be considered the gold standard. A bivariate 
plot will be constructed and Pearson’s Correlation Coefficient, r will be 
calculated for the novel device against the laboratory FBC. This will be 
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8.4.Protocol for Study III 
DETAILED PROTOCOL FOR: 
A novel, non-invasive device for the estimation of stroke volume – 
comparison with continuous thermodilution technique 
Broderick*, U. Timm†, G. Leen†, E. Lewis†, D. Breen**, S. Allen* 
*Green Lane Department of Cardiothoracic Anaesthesia, Auckland City 
Hospital, Auckland, New Zealand. †Optical Fibre Research Centre, 
University of Limerick, Ireland. **Department of Anaesthesia, Intensive 
Care and Pain Medicine, Cork University Hospital, Cork, Ireland. 
Introduction 
There is no gold standard for the clinical measurement of cardiac output 
and stroke volume, although the bolus thermodilution technique via 
pulmonary artery catheters (PACs) has been accepted as a “practical” 
gold standard since the 1970s1. However, this technique is associated 
with complications2, 3 and inherent error of up to 20%1. The continuous 
thermodilution cardiac output (CCO) technique has been shown to agree 
clinically with the bolus thermodilution technique in several studies4, 5. 
Over the last number of years, various devices have been developed to 
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allow measurement of cardiac output and stroke volume (PiCCO, LiDCO, 
Doppler oesophageal probes, partial CO2 re-breathing, etc). Apart from 
bioimpedance methods (such as NICOM6), none of these methods are 
truly non-invasive. 
A rapidly responding, automated and truly non-invasive measurement of 
cardiac output, stroke volume or fluid responsiveness would avoid the 
complications of more invasive methods, and could allow for easier goal-
directed management of surgical patients.  
It is known that the arterial pulse pressure variation (PPV), a system based 
on analysing the arterial pressure waveform, can reflect cardiac output 
and predict fluid responsiveness7. 
Studies have shown that the information derived from the pulse oximetry 
plethysmograph (pulse oximetry plethysmograph variation or POPV) is as 
good as PPV for predicting fluid responsiveness8 and is a reliable 
indicator of mild hypovolaemia in anaesthetised patients9. However, 
none of the POPV systems (which are no more invasive than a standard 
pulse oximetry probe) present automated data.  
Masimo have developed various devices, which measure the 
“plethysmograph variability index” or PVI. PVI is a measure of the 
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variation in the perfusion index (PI) which is calculated from the formula 
PI=(AC/DC) x 100 (where AC is the varying portion of the light 
absorbance signal caused by pulsatile blood flow, and DC is the constant 
portion of the light absorbance signal caused by skin, muscle, tendon, 
bone, and venous (non-pulsatile) blood)10. Changes in PVI have been 
shown to reflect changes in POPV10, and therefore has the potential to 
be used as a guide to fluid management of intraoperative patients11. 
The Optical Fibre Sensor Research Centre at the University of Limerick 
(UL) together with the Institute of General Electrical Engineering at the 
University of Rostock, Germany have co-developed a novel device which 
has the potential to non-invasively and automatically process the pulse 
oximetry plethysmograph to calculate indices based on stroke volume/
fluid responsiveness12. The device is based on a novel mathematical 
analytical process, which potentially can provide a continuous and 
automatic indirect measure of stroke volume/cardiac output. It does not 
rely on PI or PVI, but instead analyses the beat-to-beat changes in the 
area-under-the-curve of the plethysmograph to reflect stroke volume13. 
As the device is entirely non-invasive, it avoids the specific complications 
associated with PACs and other methods of cardiac output 
measurement. There are potential cost-savings in that the use of more 
expensive cardiac output measurement devices could be avoided. The 
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ease of use associated with such a non-invasive device would allow more 
flexible usage and if it could reliably predict responsiveness to fluid 
administration it may result in clinical benefits associated with systems 
which have already be shown to predict fluid responsiveness14. 
Objectives 
To examine whether there is a correlation between the indices of cardiac 
output/stroke volume as measured by the novel device and the cardiac 
index as measured by the continuous thermodilution technique. 
To examine the relationship between increases in 
cardiac index (continuous thermodilution technique) 
following a fluid bolus and increases in such indices of 
cardiac output/stroke volume as measured by the novel 
device. 
Hypothesis 
That the displayed analysis the pulse oximetry plethysmographic 
waveform by a novel, automated, non-invasive device can correlate with 
cardiac output/stroke volume (as measured using the continuous 
thermodilution technique) in anaesthetised, ventilated and 
haemodynamically stable patients about to undergo cardiac surgery. 
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That this novel, automated, non-invasive device can detect a positive 
response (measured as an increase in a marker of stroke volume/cardiac 
output), or lack thereof, to a fluid bolus in anaesthetised, ventilated and 
haemodynamically stable patients about to undergo cardiac surgery (as 
detected using the continuous thermodilution technique). 
Study Design 
A prospective observational study. 
Setting 
This study will take place entirely at Auckland City Hospital, Auckland, 
New Zealand. Patients enrolled will be those undergoing cardiac surgical 
procedures who, in the opinion of the attending anaesthetist, require a 
pulmonary artery catheter (PAC) to be inserted prior to commencement 
of the procedure as part of their ordinary management. 
Sample Size 





• Patients due to undergo cardiac surgery 
• PAC required to be inserted prior to commencement of surgery 
Exclusion Criteria 
• Patient refusal (or inability to provide full informed consent) 
• Ejection fraction <30% (avoids potential difficulties with giving the 
fluid bolus) 
• Cardiac arrhythmias present at induction 
• Known moderate (or worse) tricuspid regurgitation (makes 
thermodilution estimates of CO inaccurate) 
• Known moderate (or worse) aortic regurgitation (previous studies 
using pulse contour analysis have excluded these – causes an 
abnormal pulse signal) 
• Presence of an intra-aortic balloon counterpulsation device (cause 
an abnormal pulse signal, device may give inaccurate readings) 




Following local ethical approval and with the informed written consent of 







Following attachment of routine monitors, and insertion of an arterial line 
for invasive blood pressure monitoring, anaesthesia will be induced and 
a pulmonary artery catheter will be inserted. The novel device will be 
placed on an appropriate finger. Once cardiac index (CI) has stabilised, 
baseline haemodynamic data (HR, MAP, CVP, CI (the three latest 
readings), and the reading from the novel device) will be recorded. A 
fluid bolus of crystalloid (Plasma-Lyte 148) (7mL/kg at 1mL/kg/min, based 
on previous studies17) will be given. A second set of haemodynamic 
readings will be taken two minutes following completion of the fluid 
bolus. No changes to ventilatory settings, rates of inotrope/vasopressor 
delivery (if any), or rate of IV fluid administration (other than the fluid 
bolus) will be made between data recording points. In addition, no 
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supplemental vasoactive drugs will be given between data recording 
points. 
Data Management 
Readings of CI taken from the PAC using the continuous thermodilution 
technique will be considered the ‘gold standard’. The precision of the 
PAC will be determined using the three consecutive readings taken each 
time. Scatter plots will be constructed of CI (from the PAC) against the 
readings from the novel device and linear regression analysis performed. 
Pearson’s correlation coefficient will be calculated. Polar plots will be 




1. Pugsley J, Lerner AB: Cardiac Output Monitoring: Is There a Gold 
Standard and How Do the Newer Technologies Compare? Semin 
Cardiothorac Vasc Anesth 2010; 14: 274-82  
2. Coulter TD, Wiedemann HP: Complications of Hemodynamic 
Monitoring. Clin Chest Med 1999; 20: 249-67  
3. Evans D, Doraiswamy V, Prosciak M, Silviera M, Seamon M, Funes RV 
et al: Complications Associated with Pulmonary Artery Catheters: A 
Comprehensive Clinical Review. Scand J Surg 2009; 98: 199-208  
4. Lefrant J, Bruelle P, Ripart J, Ibanez F, Aya G, Peray P et al: Cardiac 
output measurement in critically ill patients: comparison of continuous 
and conventional thermodilution techniques. Can J Anaesth 1995; 42: 
972-6  
5. Rödig G, Keyl C, Liebold A, Hobbhahn J: Intra-operative evaluation of 
a continuous versus intermittent bolus thermodilution technique of 
cardiac output measurement in cardiac surgical patients. Eur J 
Anaesthesiol 1998; 15: 196-201  
6. Squara P, Denjean D, Estagnasie P, Brusset A, Dib J, Dubois C: 
Noninvasive cardiac output monitoring (NICOM): a clinical validation. 
Intens Care Med 2007; 33: 1191-4  
7. Kramer A, Zygun D, Hawes H, Easton P, Ferland A: Pulse Pressure 
Variation Predicts Fluid Responsiveness Following Coronary Artery 
198
Bypass Surgery. Chest 2004; 126: 1563-8  
8. Natalini G, Rosano A, Taranto M, Faggian B, Vittorielli E, Bernardini A: 
Arterial Versus Plethysmographic Dynamic Indices to Test 
Responsiveness for Testing Fluid Administration in Hypotensive Patients: 
A Clinical Trial. Anesth Analg 2006; 103: 1478-84  
9. Pizov R, Eden A, Bystritski D, Kalina E, Tamir A, Gelman S: Arterial and 
Plethysmographic Waveform Analysis in Anesthetized Patients with 
Hypovolemia. Anesthesiology 2010; 113: 83-91  
10. Cannesson M, Delannoy B, Morand A, Rosamel P, Attof Y, Bastien O, 
Lehot J-J: Does the Pleth Variability Index Indicate the Respiratory-
Induced Variation in the Plethysmogram and Arterial Pressure 
Waveforms? Anesth Analg 2008; 106: 1189-94  
11. Forget P, Lois F, Kock M de: Goal-directed fluid management based 
on the pulse oximeter-derived pleth variability index reduces lactate 
levels and improves fluid management. Anesth Analg 2010; 111: 910-4  
12. Timm U, Andruschenko S, Hinz M, Koball S, Leen G, Lewis E, Kraitl J, 
Ewald H: Optical sensor system for continuous non-invasive 
hemodynamic monitoring in real-time. IEEE Sensors Appl Symp 2011: 
167-72 
13. Andruschenko S, Timm U, Hinz M, Koball S, Kraitl J, Lewis E, Ewald 
H: Pulse spectroscopy system for non-invasive real-time monitoring of 
the heart beat volume. Proc. 9 IEEE International Conference on Sensors, 
2010: 1863-8 
199
14. Gan TJ, Soppitt A, Maroof M, El-Moalem H, Robertson KM, Moretti E 
et al: Goal-directed Intraoperative Fluid Administration Reduces Length 
of Hospital Stay after Major Surgery. Anesthesiology 2002; 97: 820-6  
15. Goedje O, Hoeke K, Lichtwarck-Aschoff M, Faltchauser A, Lamm P, 
Reichart B: Continuous cardiac output by femoral arterial thermodilution 
calibrated pulse contour analysis: Comparison with pulmonary arterial 
thermodilution. Crit Care Med 1999; 27: 2407-12  
16. Zimmermann M, Feibicke T, Keyl C, Prasser C, Moritz S, Graf BM, 
Wiesenack C: Accuracy of stroke volume variation compared with pleth 
variability index to predict fluid responsiveness in mechanically ventilated 
patients undergoing major surgery. Eur J Anaesth 2010; 27: 555-61  
17. Wiesenack C, Fiegl C, Keyser A, Prasser C, Keyl C: Assessment of 
fluid responsiveness in mechanically ventilated cardiac surgical patients. 
Eur J Anaesth 2005; 22: 658-5  
18. Critchley LA, Lee A, Ho A: A Critical Review of the Ability of 
Continuous Cardiac Output Monitors to Measure Trends in Cardiac 
Output. Anesth Analg 2010; 111: 1180-92  
200
8.5.Data Set for Study I 
Key to Data Set 
N = data missing 
N/A = variable has no units or value is continuous/not defined 
Variable Name Variable Label Units Variable Values
No Patient Number N/A N/A
Age Patient’s Age Years N/A
Sex Patient’s Gender N/A F=female 
M=male
Hgt Patient’s Height Centimetres N/A






















Smoke Smoking History N/A 0=Never 
1=Previous 
2=Active
PackYr Pack Years 
Smoked
Years N/A




Device HB1 Novel Device 
Haemoglobin (1)
Grams per litre N/A
Device HB2 Novel Device 
Haemoglobin (2)
Grams per litre N/A
Device HB3 Novel Device 
Haemoglobin (3)
Grams per litre N/A
Device HB4 Novel Device 
Haemoglobin (4)
Grams per litre N/A
BGA Hb1 Blood Gas 
Analyser 
Haemoglobin (1)
Grams per litre N/A
BGA Hb2 Blood Gas 
Analyser 
Haemoglobin (2)
Grams per litre N/A
BGA Hb3 Blood Gas 
Analyser 
Haemoglobin (3)
Grams per litre N/A
Variable Name Variable Label Units Variable Values
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BGA Hb4 Blood Gas 
Analyser 
Haemoglobin (4)
Grams per litre N/A
FBC Hb1 Full Blood Count 
Haemoglobin (1)
Grams per litre N/A
FBC Hb2 Full Blood Count 
Haemoglobin (2)
Grams per litre N/A
FBC Hb3 Full Blood Count 
Haemoglobin (3)
Grams per litre N/A
FBC Hb4 Full Blood Count 
Haemoglobin (4)
Grams per litre N/A
HB coeff1 Haemoglobin 
coefficient (1)
N/A N/A
HB coeff2 Haemoglobin 
coefficient (2)
N/A N/A
HB coeff3 Haemoglobin 
coefficient (3)
N/A N/A
HB coeff4 Haemoglobin 
coefficient (4)
N/A N/A
Variable Name Variable Label Units Variable Values
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No Age Sex Hgt Wgt Proc HB Temp Smoke PackYr Cess
1 71 F 156 56 1 14.1 36 1 20 408
2 65 M 177 81.4 1 14.6 36 0 0 0
3 59 M 161 147.4 1 16.3 36 1 58.75 1.5
4 34 M 165 79.8 1 15.3 36.6 0 0 0
5 70 M 172 88 2 13.3 36.8 0 0 0
6 80 F 161.5 65.6 1 11.9 36 0 0 0
7 71 M 171 67 0 13 36 0 0 0
8 71 F 155 58 1 12 36 0 0 0
9 67 F 152 91.6 1 14.7 36 0 0 0
10 74 M 163.5 84.1 0 15.2 36.2 0 0 0
11 78 M 158 80 0 12.9 36.4 0 0 0
12 80 M 179 75 0 14.8 37 1 2 732
13 54 M 167.3 95.2 0 11.4 36.2 1 45 1.75
14 57 F 163 74.2 1 13.5 36.8 0 0 0
15 49 F 163 68 3 13.1 36.5 0 0 0
16 67 F 159 57.4 0 13.1 36 0 0 0
17 55 M 184 92.3 0 15.9 36.5 0 0 0
18 55 M 170 80.8 0 15.2 36.5 1 7.5 18
19 72 M 180 76.5 0 12.4 36.2 1 22.5 120
20 74 M 168 72.8 0 11 36.1 1 1 480
21 62 M 177.8 93.6 0 15.3 36.4 2 84 0
22 78 F 157.9 51 2 11.9 36.1 0 0 0
23 47 M 170 97.6 0 13.9 36.5 1 2.5 12
24 66 F 160 80 2 12.3 36.4 0 0 0



















1 13.2 15.6 11.4 14 12.9 14.1 8.4 9.5
2 12.1 13 15.5 15.5 13.4 13.4 10.5 11.6
3 12.8 13.8 12.7 11.8 14.9 14.5 11.4 11.6
4 14.9 12.7 10.2 12.4 12.8 12.3 8.3 8.9
5 15.2 13.3 10.3 10.2 12.1 11.7 8.1 N
6 11.4 N 12.4 11.8 12.4 N 8.5 8.9
7 12 13.9 12.6 12.4 11.3 11.4 8 8.7
8 11.6 12 9.7 12.2 10.3 10.2 6.9 6.8
9 12.6 13.8 13.1 12.3 13.1 13.3 9.3 9.1
10 13.4 11.7 11.8 N 12.7 13.1 9.2 N
11 10.3 12.9 12.3 11.8 11 10.6 8.1 8.4
12 14.8 13.8 9.7 10.5 13 12.9 10.5 10.6
13 19 15.5 13.6 13.2 11.7 11.8 8.5 9.3
14 11.7 17.9 16.5 15.6 11.7 10 7.7 7.7
15 12.9 14 13.2 17.9 11.2 11.4 6 8.2
16 9.7 9.2 14 12 11.1 9.9 7 7.5
17 16 13.7 12.1 10.9 13.6 13.9 9.4 10.4
18 13.8 11.9 18.5 11.6 13 13.6 9.9 10.8
19 10.1 12.1 13.3 8.8 11.4 10.8 6.5 8.6
20 11.4 12.4 11.6 8.2 9.9 9.8 6.7 7.6
21 18.5 15.4 10.7 11.3 13 13.4 10.2 11.3
22 14.4 13.5 12.4 9.5 9.7 9.7 6.7 8.1
23 13.5 14.5 13.8 12.4 13.4 13.3 9 10.3
24 12 12.3 12.7 11.2 11.3 11.1 7.5 8.6



















1 12.8 13.9 8.3 9.2 2.5 N 1.7 1.6
2 13 13.1 10.4 11.2 1.1 0.45 N N
3 14.2 13.8 11 11.3 N N 0.8 1.5
4 13.1 12.6 8.3 8.7 N N N N
5 11.8 11.5 8.4 9.7 N N N N
6 12 N 7.6 8.4 1.5 N 1.1 1.4
7 10.9 11.1 7.8 8.9 N 2.2 1 1
8 9.8 9.7 6.6 6.5 N 1.8 N N
9 12.9 12.7 9.1 N 1 1.8 N N
10 13.3 12 9.8 N 1.5 1.6 1.7 N
11 10.9 10.9 7.9 8 2.1 1.4 2 N
12 13 13 10.3 10.5 2.6 1.3 N N
13 11.4 11.2 8.7 9 1.2 1.1 N N
14 N 10.1 7.6 7.2 N N N N
15 11.1 11.3 6.3 8.3 N N 2.5 1.7
16 11.5 9.7 7.2 7.7 N N 1.7 1.8
17 13 13.4 9.7 10.2 2.1 1 0.9 0.8
18 13 13 10 11.1 N N N N
19 10.8 10 7.1 8.2 2.2 1.9 2.4 N
20 9.3 9 7 7.6 2.2 1.8 N N
21 12.8 12.5 9.9 11.1 1.1 1.3 N N
22 9 9.1 6.5 8.1 1.8 2.3 2.1 2.2
23 12.8 12.4 8.9 9.6 N N N N
24 10.5 10.7 7.2 8.1 N N N N
25 11.6 12 8.7 8.9 1.9 1.9 2 N
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8.6.Data Set for Study II 
Key to Data Set 
N = data missing 
N/A = variable has no units or value is continuous/not defined 
Variable Name Variable Label Units Variable Values
No Patient Number N/A N/A
Hgt Patient’s Height Centimetres N/A
Wgt Patient’s Weight Kilograms N/A





Dev Hb Device 
Haemoglobin
Grams per litre N/A
FBC Hb Full Blood Count 
Haemoglobin
Grams per litre N/A
Smoke Smoking History N/A 0=Never 
1=Previous 
2=Active









Temp Temperature Degrees 
Centigrade
N/A
Variable Name Variable Label Units Variable Values
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Smoke Cigs Cess Temp
1 160 63.4 25.00 12.60 10.90 1 10 120 N
2 160 64.0 25.00 17.80 11.20 0 0 0 36.8
3 159 67.7 26.80 17.50 11.30 0 0 0 36.7
4 161 67.2 25.90 15.90 12.30 1 10 3.46 36.9
5 164 104.9 39.00 17.50 11.60 0 0 0 36.7
6 164 71.9 26.80 17.50 11.10 0 0 0 36.6
7 164 73.6 27.40 13.50 11.30 0 0 0 36.8
8 164 58.1 21.60 13.70 11.70 1 5 48 36.5
9 158 56.8 22.80 17.50 12.40 0 0 0 37.0
10 170 59.0 20.40 13.30 11.60 0 0 0 36.6
11 175 72.0 23.50 13.60 12.20 0 0 0 36.9
12 154 61.2 25.80 11.70 11.50 0 0 0 36.7
13 165 59.1 21.70 14.10 11.10 1 10 4.62 36.7
14 162 53.0 20.20 16.80 11.10 0 0 0 36.6
15 172 69.9 23.70 16.70 10.00 1 10 5 36.6
16 174 74.1 24.40 15.60 12.80 1 10 108 36.5
17 173 63.0 23.10 16.00 12.40 0 0 0 37.1
18 N N 24.40 13.50 11.30 0 0 0 N
19 168 76.0 27.10 12.10 12.30 0 0 0 N
20 165 84.1 28.30 13.30 11.30 2 6 0 N
21 163 95.8 33.50 13.50 12.70 1 N 108 N
22 178 76.7 23.00 13.00 12.50 0 0 0 N
23 157 78.0 31.60 12.00 13.40 0 0 0 N
24 160 67.0 26.20 13.10 11.40 0 0 0 N
25 155 64.0 26.40 14.10 12.20 1 N 96 N
26 158 78.6 29.90 12.40 11.60 0 0 0 N
27 170 114.9 37.60 13.00 11.80 0 0 0 N
28 168 64.0 22.60 12.00 10.70 0 0 0 N
29 150 62.5 27.80 12.20 12.00 0 0 0 N
30 159 87.9 37.10 12.00 11.80 0 0 0 N
31 163 84.4 31.60 13.90 11.40 2 3 0 N
32 170 73.7 24.60 13.50 9.60 0 0 0 N
33 165 69.0 25.30 12.20 13.20 2 5 0 N
34 168 78.7 26.70 12.20 10.80 0 0 0 N
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35 158 58.9 23.40 11.20 10.80 2 10 0 N
36 161 59.0 22.80 13.40 12.20 1 N 4 N
37 168 71.7 24.50 12.50 10.70 2 10 0 N
38 154 49.0 20.70 11.60 11.40 0 0 0 N
39 152 74.0 31.20 13.70 10.90 0 0 0 N
40 161 52.2 19.80 12.60 10.60 0 0 0 N
41 162 69.9 26.70 11.20 12.30 2 2 0 N
42 170 68.0 23.50 12.30 12.90 1 6 48 N
43 166 84.0 32.30 13.80 12.10 2 8 0 N
44 161 72.5 28.10 13.60 9.90 0 0 0 N
45 171 61.5 21.10 11.70 11.60 1 1 6 N
46 171 70.3 24.10 13.80 12.50 0 0 0 N
47 171 87.3 29.80 13.50 11.90 0 0 0 N
48 161 62.0 23.90 11.30 13.30 1 1.5 36 N
49 152 61.4 25.90 13.20 11.80 1 3 6 N
50 163 55.6 21.10 11.30 11.80 0 0 0 N
51 161 70.0 27.00 10.70 10.60 1 20 72 N
52 161 92.2 35.60 14.10 11.50 0 0 0 N
53 172 80.5 27.20 12.90 12.40 0 0 0 N
54 162 59.8 22.90 12.70 11.80 0 0 0 N
55 165 86.0 31.60 11.10 11.30 0 0 0 N
56 166 65.2 23.60 11.40 9.90 0 0 0 N
57 169 72.2 25.20 13.50 12.70 0 0 0 N
58 163 62.0 23.50 10.60 10.90 0 0 0 N
59 166 62.6 22.70 11.10 10.90 0 0 0 N
60 157 72.2 29.30 12.20 11.40 2 3 0 N
61 168 82.2 29.30 12.20 11.50 0 0 0 N
62 162 70.0 26.70 13.20 13.00 0 0 0 N
63 153 84.0 35.90 10.80 12.20 0 0 0 N
64 166 63.8 23.30 12.00 10.20 0 0 0 N
65 156 72.9 29.90 12.20 12.80 0 0 0 N
66 168 64.9 22.60 11.80 10.80 0 0 0 N
67 165 65.3 24.00 12.50 10.40 0 0 0 N
68 177 75.0 23.90 12.40 11.50 0 0 0 N





Smoke Cigs Cess Temp
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69 165 101.8 37.50 11.10 11.90 0 0 0 N
70 162 60.6 23.10 10.50 12.20 0 0 0 N
71 167 97.1 35.10 11.60 10.10 1 8 6 N
72 166 76.0 27.60 11.20 13.30 1 N 192 N
73 170 93.2 32.20 10.40 13.20 0 0 0 N
74 161 101.0 39.00 12.80 12.80 1 10 5 N
75 158 58.3 23.20 11.60 11.50 0 0 0 N
76 168 66.0 23.40 11.10 7.50 2 10 0 N
77 155 58.1 24.40 11.10 11.00 0 0 0 N
78 164 83.6 31.10 11.80 11.50 0 0 0 N
79 156 72.0 29.60 10.80 12.20 1 N 120 N
80 163 74.4 27.10 10.90 12.10 1 10 24 N
81 167 75.0 27.10 13.60 12.00 0 0 0 N
82 175 80.0 26.10 12.10 12.70 1 10 36 N
83 166 70.0 25.40 12.80 13.00 1 1 6 N
84 154 58.0 24.50 11.40 12.60 0 0 0 N
85 176 80.0 25.80 11.70 12.50 0 0 0 N
86 176 96.3 31.10 11.20 12.70 0 0 0 N
87 163 68.0 25.60 10.80 13.20 1 5 5 N
88 172 73.0 24.70 10.90 11.70 1 20 12 N
89 168 86.0 30.50 13.90 13.40 1 10 4 N
90 167 94.0 32.90 12.40 12.40 0 0 0 N
91 161 82.9 31.90 12.80 11.10 1 N 180 N
92 178 105.7 33.40 12.30 11.90 1 N 10 N
93 176 88.3 28.70 13.00 14.00 0 0 0 N
94 168 62.2 22.20 12.10 10.40 2 6 0 N
95 159 77.2 30.50 10.40 10.40 1 1 24 N
96 163 72.4 27.10 11.20 11.00 1 20 24 N
97 161 63.2 24.40 13.10 11.80 0 0 0 N
98 161 62.9 24.30 12.00 10.20 2 3 0 N
99 168 95.0 33.70 11.80 13.10 0 0 0 N
100 157 59.4 24.30 11.10 10.70 1 N 120 N





Smoke Cigs Cess Temp
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8.7.Data Set for Study III 
Key to Data Set 
N = data missing 
N/A = variable has no units or value is continuous/not defined 
Variable Name Variable Label Units Variable Values
No Patient Number N/A N/A





Hgt Patient’s Height Centimetres N/A
Wgt Patient’s Weight Kilograms N/A























































Sys1 Systolic blood 






Variable Name Variable Label Units Variable Values
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Sys3 Systolic blood 






Sys4 Systolic blood 













Sys6 Systolic blood 






Dia1 Diastolic blood 






Variable Name Variable Label Units Variable Values
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Dia3 Diastolic blood 






Dia4 Diastolic blood 













Dia6 Diastolic blood 






MAP1 Mean arterial 






Variable Name Variable Label Units Variable Values
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MAP3 Mean arterial 






MAP4 Mean arterial 













MAP6 Mean arterial 






CVP1 Central venous 






Variable Name Variable Label Units Variable Values
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CVP3 Central venous 






CVP4 Central venous 













CVP6 Central venous 













Variable Name Variable Label Units Variable Values
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CO1 Cardiac output 












CO3 Cardiac output 





Variable Name Variable Label Units Variable Values
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CO4 Cardiac output 












CO6 Cardiac output 





SV1 Stroke volume 
at first reading 
pre-bolus
Millilitres N/A





SV3 Stroke volume 
at third reading 
pre-bolus
Millilitres N/A
SV4 Stroke volume 
at first reading 
post-bolus
Millilitres N/A
Variable Name Variable Label Units Variable Values
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SV6 Stroke volume 
at third reading 
post-bolus
Millilitres N/A
Dev1 Device output 
at first reading 
pre-bolus
N/A N/A





Dev3 Device output 
at third reading 
pre-bolus
N/A N/A
Dev4 Device output 
at first reading 
post-bolus
N/A N/A





Variable Name Variable Label Units Variable Values
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Dev6 Device output 
at third reading 
post-bolus
N/A N/A












Variable Name Variable Label Units Variable Values
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No Age Sex Hgt Wgt BSA Proc Bolus
1 73 F 161 61 1.64 0, 1 427
2 39 F 162 90 1.94 1 630
3 83 M 170 70 1.81 1 N
4 28 F 170 121 2.28 2, 3 847
5 65 M 162 79 1.84 0 551
6 60 F 163 65 1.70 3 455
7 66 M 175 82.6 1.98 0 578
8 65 M 167 79.4 1.88 0 555
9 80 M 172 72.5 1.85 0 507.5
10 67 M N N N N N
11 56 M 172 108 2.19 0 756
12 64 F 159 66 1.68 0 461
13 76 F 164 75 1.82 2 523
14 62 M 179 105 2.23 0, 3 735
15 72 M 165 74 1.81 0 516
16 N N N N N N N
17 64 F 155 64 1.63 0 448
18 54 M 177 75 1.92 0 525
19 62 M 165 71 1.78 0 497
20 75 M 173 74 1.88 0 515
21 N N N N N N N
22 77 M 172 77 1.90 0, 1 539
23 64 M 170 80 1.92 0 560
24 65 F 163 96 2.01 0 672
25 55 M 187 81 2.06 0 567
222
No HR1 HR2 HR3 HR4 HR5 HR6
1 58 57 58 65 68 57
2 76 64 63 95 77 75
3 N N N N N N
4 89 88 86 78 79 78
5 59 59 56 53 52 51
6 45 45 44 44 42 42
7 61 62 63 61 63 64
8 65 64 63 57 58 58
9 60 61 63 63 62 65
10 N N N N N N
11 74 74 74 74 80 79
12 54 54 55 77 71 60
13 70 72 70 70 70 70
14 52 51 52 61 56 60
15 53 52 53 53 50 48
16 N N N N N N
17 67 73 69 70 69 69
18 43 43 42 43 43 43
19 81 81 79 80 81 79
20 54 53 52 56 57 55
21 N N N N N N
22 74 74 74 74 74 74
23 74 78 77 77 75 76
24 53 51 51 50 48 50
25 45 39 39 39 38 38
223
No Sys1 Sys2 Sys3 Sys4 Sys5 Sys6
1 125 131 118 109 125 101
2 130 99 95 125 134 117
3 N N N N N N
4 87 85 78 94 86 83
5 108 103 89 78 74 70
6 105 105 107 126 104 103
7 80 79 78 89 88 100
8 105 101 99 95 97 91
9 109 103 96 89 86 84
10 N N N N N N
11 104 101 103 110 128 117
12 112 105 109 121 140 123
13 121 111 107 142 134 125
14 116 117 121 123 120 118
15 137 133 130 156 146 138
16 N N N N N N
17 126 135 140 142 140 133
18 98 92 87 99 95 90
19 169 158 148 123 121 116
20 158 156 149 128 125 121
21 N N N N N N
22 113 110 108 109 104 99
23 126 109 119 126 136 132
24 123 119 115 124 121 114
25 114 115 123 105 101 98
224
No Dia1 Dia2 Dia3 Dia4 Dia5 Dia6
1 70 74 67 63 72 55
2 81 53 50 76 75 65
3 N N N N N N
4 50 47 47 54 51 49
5 28 53 48 42 40 38
6 43 44 45 83 87 87
7 40 40 33 48 47 54
8 60 58 57 54 52 53
9 49 45 42 43 41 40
10 N N N N N N
11 59 58 58 63 77 67
12 51 29 51 57 71 59
13 66 61 60 75 70 67
14 59 58 60 64 62 61
15 65 63 63 72 69 64
16 N N N N N N
17 69 75 76 73 72 70
18 55 52 48 55 53 50
19 93 90 86 72 71 69
20 73 73 70 61 60 59
21 N N N N N N
22 49 48 47 51 48 46
23 74 61 69 70 78 75
24 60 58 57 59 57 51
25 59 55 59 47 44 43
225
No MAP1 MAP2 MAP3 MAP4 MAP5 MAP6
1 91 97 84 81 94 73
2 101 70 56 92 93 87
3 N N N N N N
4 60 60 57 64 62 59
5 68 70 62 55 52 49
6 64 64 66 95 93 93
7 52 51 49 60 59 70
8 76 74 72 69 68 67
9 72 65 63 60 60 59
10 N N N N N N
11 73 72 73 78 93 85
12 71 67 70 82 98 84
13 85 78 79 100 93 89
14 77 78 80 86 81 80
15 91 85 86 105 96 90
16 N N N N N N
17 89 95 98 98 96 92
18 72 69 64 73 70 66
19 124 117 111 94 92 89
20 107 105 101 86 84 82
21 N N N N N N
22 73 72 70 73 70 66
23 93 77 87 90 101 97
24 82 79 77 82 80 73
25 77 73 79 64 61 59
226
No CVP1 CVP2 CVP3 CVP4 CVP5 CVP6
1 4 6 4 5 5 5
2 12 10 10 14 16 16
3 N N N N N N
4 13 11 11 N 15 14
5 N N N 10 10 11
6 11 11 11 15 14 13
7 8 7 7 8 7 8
8 14 13 14 15 15 15
9 5 4 4 6 6 6
10 N N N N N N
11 12 12 12 13 14 14
12 12 12 12 14 14 14
13 8 9 8 12 11 11
14 9 9 9 10 11 11
15 11 11 10 11 11 11
16 N N N N N N
17 21 22 22 24 23 23
18 5 5 5 7 6 6
19 5 6 5 7 7 7
20 10 10 10 14 14 11
21 N N N N N N
22 4 4 3 6 6 5
23 6 6 6 8 8 8
24 9 9 9 13 13 6
25 3 3 4 6 5 6
227
No CI1 CI2 CI3 CI4 CI5 CI6
1 3.4 2.8 1.8 2.5 2.4 2.7
2 2.3 2.2 2.1 1.9 1.8 1.9
3 N N N N N N
4 1.4 0.9 0.9 1.3 0.6 0.9
5 2.4 3.6 3 3.2 3.1 3.1
6 3.2 3.1 3.2 3.4 3.3 3
7 2.8 2.8 3 3 3.4 3.3
8 2.5 2.3 2.3 2.3 2.3 2.3
9 1.7 1.7 1.6 2 2 2
10 N N N N N N
11 2.5 2.2 2.3 2 2 2.1
12 1.8 1.8 1.8 2.3 2.8 2.9
13 1.9 2.2 1.7 2.5 2.3 2.3
14 2.9 2.8 2.7 2.1 2.2 2.3
15 3.3 2.8 2.5 2.4 2.3 2.4
16 N N N N N N
17 1.9 2 2 2 2.1 2.1
18 2 2 1.9 1.7 1.9 2
19 1.8 2 2 2.3 2.2 2.3
20 2.6 2.4 2.4 3.3 3.5 2.5
21 N N N N N N
22 2.5 3.1 2.8 2.7 2.8 2.7
23 1.9 2 1.9 2.1 2.1 2.3
24 2.2 2.4 2.3 1.8 2 2
25 3.7 4.5 4.1 3 3.1 3.1
228
No CO1 CO2 CO3 CO4 CO5 CO6
1 5.58 4.59 2.95 4.10 3.94 4.43
2 4.47 4.28 4.08 3.69 3.50 3.69
3 N N N N N N
4 3.20 2.06 2.06 2.97 1.37 2.06
5 4.42 6.62 5.52 5.89 5.70 5.70
6 5.44 5.27 5.44 5.78 5.61 5.10
7 5.55 5.55 5.95 5.95 6.74 6.54
8 4.71 4.33 4.33 4.33 4.33 4.33
9 3.15 3.15 2.96 3.71 3.71 3.71
10 N N N N N N
11 5.49 4.83 5.05 4.39 4.39 4.61
12 3.03 3.03 3.03 3.87 4.71 4.88
13 3.45 3.99 3.09 4.54 4.18 4.18
14 6.47 6.25 6.03 4.69 4.91 5.13
15 5.98 5.08 4.53 4.35 4.17 4.35
16 N N N N N N
17 3.10 3.26 3.26 3.26 3.42 3.42
18 3.84 3.84 3.65 3.26 3.65 3.84
19 3.21 3.56 3.56 4.10 3.92 4.10
20 4.88 4.50 4.50 6.19 6.57 4.69
21 N N N N N N
22 4.75 5.89 5.32 5.13 5.32 5.13
23 3.64 3.83 3.64 4.02 4.02 4.41
24 4.42 4.82 4.62 3.61 4.02 4.02
25 7.63 9.28 8.46 6.19 6.40 6.40
229
No SV1 SV2 SV3 SV4 SV5 SV5
1 96.19 80.61 50.92 63.11 57.91 77.73
2 58.85 66.84 64.82 38.89 45.46 49.26
3 N N N N N N
4 35.92 23.36 23.90 38.06 17.34 26.35
5 74.84 112.26 98.56 111.08 109.68 111.83
6 120.96 117.18 123.71 131.44 133.65 121.50
7 91.02 89.55 94.42 97.52 107.01 102.24
8 72.49 67.73 68.81 76.05 74.74 74.74
9 52.49 51.63 47.05 58.81 59.76 57.00
10 N N N N N N
11 74.14 65.24 68.21 59.31 54.86 58.33
12 56.05 56.05 55.03 50.23 66.31 81.27
13 49.28 55.48 44.09 64.84 59.66 59.66
14 124.48 122.54 115.89 76.84 87.68 85.56
15 112.90 97.64 85.53 82.11 83.41 90.66
16 N N N N N N
17 46.20 44.64 47.22 46.55 49.59 49.59
18 89.25 89.25 86.81 75.86 84.79 89.25
19 39.59 43.99 45.11 51.22 48.39 51.87
20 90.36 84.98 86.61 110.59 115.23 85.30
21 N N N N N N
22 64.21 79.62 71.91 69.34 71.91 69.34
23 49.18 49.11 47.26 52.24 53.63 57.97
24 83.33 94.47 90.54 72.27 83.65 80.30
25 169.65 238.07 216.91 158.71 168.32 168.32
230
No Dev1 Dev2 Dev3 Dev4 Dev5 Dev6 Excl
1 0.92 0.55 3.53 1.51 1.13 3.48 N/A
2 0.37 2.75 3.22 0.35 0.26 0.29 N/A
3 N N N N N N 0
4 N N N N N N 1
5 0.24 0.09 8.79 7.92 7.85 7.45 N/A
6 N N N N N N N/A
7 4.11 3.91 4.10 3.62 3.72 2.85 N/A
8 0.73 0.77 0.82 0.79 0.71 0.76 N/A
9 N N N N N N N/A
10 N N N N N N 2
11 2.44 2.47 2.43 1.73 1.59 0.43 N/A
12 3.94 3.36 3.09 2.70 1.76 2.59 N/A
13 3.14 3.41 3.16 0.44 0.67 1.56 N/A
14 4.58 4.87 3.80 3.92 3.80 3.93 N/A
15 0.52 0.49 0.45 0.76 0.84 0.77 N/A
16 N N N N N N 3
17 0.24 0.23 0.22 0.38 0.36 0.55 N/A
18 6.47 7.33 6.92 6.36 6.87 0.29 N/A
19 0.35 0.33 0.30 0.38 0.37 0.37 N/A
20 0.37 0.29 0.22 0.81 0.71 0.76 N/A
21 N N N N N N 3
22 2.42 2.99 3.21 0.86 1.02 1.38 N/A
23 0.42 0.65 0.33 0.27 0.30 0.33 N/A
24 7.43 7.62 7.48 6.90 6.92 6.85 N/A
25 4.26 0.97 0.43 0.93 0.70 0.99 N/A
231
